PI 1176786

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

May 27, 2004

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: *60/502,995*
FILING DATE: *September 15, 2003*
RELATED PCT APPLICATION NUMBER: *PCT/US04/07451*

By Authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS

M. Tarver

M. TARVER
Certifying Officer

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN COMPLIANCE WITH RULE 17.1(a) OR (b)

Please type a plus sign (+) inside this box → [+]

EXPRESS MAIL NO. EV324206033US

PTO/SB/16 (02-01)

Approved for use through 10/31/2002. OMB 0651-0032

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

22388 U.S. PTO 60/502995

PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53 (c).

INVENTOR(S)		
Given Name (first and middle [if any])	Family Name or Surname	Residence (City and either State or Foreign Country)
Barbara K.	Zehentner-Wilkinson	Poulsbo, Washington
Dawn C. J.	Hayes	Preston, Washington
Raymond L.	Houghton	Bothell, Washington

☐ *Additional inventors are being named on the _____ separately numbered sheets attached hereto*

TITLE OF THE INVENTION (500 characters max)

METHODS, COMPOSITIONS AND KITS FOR THE DETECTION AND MONITORING OF LUNG CANCER

CORRESPONDENCE ADDRESS

Direct all correspondence to:

☒ Customer Number 32111 → 32111 PATENT TRADEMARK OFFICE

OR *Type Customer Number here*

☐ Firm or Individual Name					
Address					
Address					
City		State		ZIP	
Country		Telephone		Fax	

ENCLOSED APPLICATION PARTS *(check all that apply)*

☒ Specification *Number of Pages* 35 ☐ CD(s), Number _____

☐ Drawing(s) *Number of Sheets* _____ ☒ Other (specify) _____

☐ Application Data Sheet. See 37 CFR 1.76

Sequence Listing (16 pages); Fee Transmittal (+ copy); Postcard.

METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT

☒ Applicant claims small entity status. See 37 CFR 1.27.

☐ A check or money order for $_____ is enclosed to cover the filing fees.

☒ The Commissioner is hereby authorized to charge filing fees to Deposit Account Number: **50-0597**

☒ The Commissioner is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account Number: **50-0597**

☐ Payment by credit card. Form PTO-2038 is attached.

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.

☒ No.

☐ Yes, the name of the U.S. Government agency and the Government contract number are: _____.

Respectfully submitted,

SIGNATURE Susan E. Lingenfelter DATE **September 15, 2003**

TYPED or PRINTED NAME **Susan E. Lingenfelter** REGISTRATION NO. *(if appropriate)* **41,156**

TELEPHONE **206-754-5898** DOCKET NUMBER: **609P2**

USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

This collection of information is required by 37 CFR 1.51. The information is used by the public to file (and by the PTO to process) a provisional application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the complete provisional application to the PTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Box Provisional Application, Commissioner for Patents, Washington, D.C. 20231.

F:\Pat\PTOSB16.doc

EXPRESS MAIL NO. EV324206033US

PTO/SB/17 (01-03)
Approved for use through 04/30/2003. OMB 0651-0032

FEE TRANSMITTAL for FY 2003

Patent fees are subject to annual revision.

☒ Applicant claims small entity status. See 37 CFR 1.27.

TOTAL AMOUNT OF PAYMENT ($) **80.00**

Complete if Known	
Filing Date	September 15, 2003
First Named Inventor	Barbara K. Zehentner-Wilkinson
Examiner Name	
Group Art Unit	
Attorney Docket No.	609P2

METHOD OF PAYMENT

☐ Payment Enclosed:
☐ Check ☐ Credit card ☐ Money Order ☐ Other

☒ Deposit Account:

Deposit Account Number: 50-0597

Deposit Account Name: Corixa Corporation

The Commissioner is authorized to *(check all that apply)*

☒ Charge fee(s) indicated below ☒ Credit any overpayments
☐ Charge any additional fee(s) during the pendency of this application
☐ Charge fee(s) indicated below, except for the filing fee
☒ Charge any deficiencies

to the above-identified deposit account.

FEE CALCULATION

1. BASIC FILING FEE

Large Entity Fee Code	Large Entity Fee($)	Small Entity Fee Code	Small Entity Fee($)	Fee Description	Fee Paid
1001	750	2001	375	Utility filing fee	
1002	330	2002	165	Design filing fee	
1003	520	2003	260	Plant filing fee	
1004	750	2004	375	Reissue filing fee	
1005	160	2005	80	Provisional filing fee	80

SUBTOTAL (1) ($) 80

2. EXTRA CLAIM FEES

			Extra Claims		Fee from below		Fee Paid
Total Claims		-** =		*		=	
Independent Claims		-** =		*		=	
Multiple Dependent				*		=	

Large Entity Fee Code	Large Entity Fee ($)	Small Entity Fee Code	Small Entity Fee ($)	Fee Description
1202	18	2202	9	Claims in excess of 20
1201	84	2201	42	Independent claims in excess of 3
1203	280	2203	140	Multiple dependent claim, if not paid
1204	84	2204	42	** *Reissue independent claims over original patent*
1205	18	2205	9	** *Reissue claims in excess of 20 and over original patent*

SUBTOTAL (2) ($)

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity Fee Code	Large Entity Fee ($)	Small Fee Code	Small Fee ($)	Fee Description	Fee Paid
1051	130	2051	65	Surcharge - late filing fee or oath	
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet.	
1053	130	1053	130	Non-English specification	
1812	2520	1812	2520	For filing a request for *ex parte* reexamination	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1840*	1805	1840*	Requesting publication of SIR after Examiner action	
1251	110	2251	55	Extension for reply within first month	
1252	410	2252	205	Extension for reply within second month	
1253	930	2253	465	Extension for reply within third month	
1254	1450	2254	725	Extension for reply within fourth month	
1255	1970	2255	985	Extension for reply within fifth month	
1401	320	2401	160	Notice of Appeal	
1402	320	2402	160	Filing a brief in support of an appeal	
1403	280	2403	140	Request for oral hearing	
1451	1510	1451	1510	Petition to institute a public use proceeding	
1452	110	2452	55	Petition to revive – unavoidable	
1453	1300	2453	650	Petition to revive – unintentional	
1501	1300	2501	650	Utility issue fee (or reissue)	
1502	470	2502	235	Design issue fee	
1503	630	2503	315	Plant issue fee	
1460	130	1460	130	Petitions to the Commissioner	
1807	50	1807	50	Processing fee for provisional applications	
1806	180	1806	180	Submission of Information Disclosure Stmt	
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1809	750	2809	375	Filing a submission after final rejection (37 CFR § 1.129(a))	
1810	750	2810	375	For each additional invention to be examined (37 CFR § 1.129(b))	
1801	750	2801	375	Request for Continued Examination (RCE)	
1802	900	1802	900	Request for expedited examination of a design application	

Other fee (specify) ____

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) ($)

Name (Print/Type)	Susan E. Lingenfelter	Registration No. Attorney/Agent	41,156
Firm Name/ Address	Corixa Corporation, 1124 Columbia Street, Suite 200, Seattle, WA 98104		
Signature	Susan E. Lingenfelter	Date	September 15, 2003

32111
PATENT TRADEMARK OFFICE

F:\Pat\ptosb17.doc

METHODS, COMPOSITIONS AND KITS FOR THE DETECTION AND MONITORING OF LUNG CANCER

TECHNICAL FIELD OF THE INVENTION

The present invention relates generally to the field of cancer diagnostics. More specifically, the present invention relates to methods, compositions and kits for the detection of lung cancer in patients with different type, stage and grade of tumors that employ oligonucleotide hybridization and/or amplification to simultaneously detect two or more tissue-specific polynucleotides in a biological sample suspected of containing lung cancer cells.

BACKGROUND OF THE INVENTION

Field of the Invention

Lung cancer remains a significant health problem throughout the world. The failure of conventional lung cancer treatment regimens can commonly be attributed, in part, to delayed disease diagnosis. Although significant advances have been made in the area of lung cancer diagnosis, there still remains a need for improved detection methodologies that permit early, reliable and sensitive determination of the presence of lung cancer cells.

Description of the Related Art

Lung cancer has the highest mortality rate of any of the cancers and is one of the most difficult to diagnose early. There are an estimated 1 million deaths annually worldwide for this disease. According to the American Cancer Society in 2002 alone there were an estimated 169,200 new cases diagnosed and ~ 154,900 deaths. Typically lung cancers are classified into two major types: Non-Small Cell Lung Carcinomas (NSCLC) comprising squamous, adeno and large cell carcinomas and Small Cell Lung Carcinomas (SCLC). These groups represent ~75% and 25% of all lung tumors respectively with adenocarcinoma and squamous cell carcinoma being the most prevalent forms of NSCLC with large cell carcinomas being ~10%. Within the group of NSCLC, adenocarcinoma is

currently the most prominent form of lung cancer in younger persons, women of all ages, lifetime nonsmokers and long-term former smokers. SCLC typically fall into two subtypes oat cell and intermediate cell. Less common tumors include carcinoid and mesotheliomas among others but these represent only a small percentage of all lung tumors. In almost all cases early diagnosis of NSCLC is elusive and most lung cancers have already metastasized by the time they are detected. Only 16.7% are localized on initial diagnosis. If tumors can be detected at a point where they are confined then the combination of chemotherapy and radiation has a possibility of success but overall the 5year prognosis is very poor with only 10-15% survival rate. The picture with SCLC is even bleaker only 6% localized at initial diagnosis and with 5 year survival rates of ~6%.

X-ray and computer tomography of the chest and abdomen are frequently used in diagnosis of lung tumors but lack sensitivity for detecting small foci and usually detect tumors that have already metastasized. Sputum cytology as a potential screening method in high-risk individuals has only been partially effective and often does not yield tumor type. To stage the disease CAT scan, MRI or bone scans are used to evaluate the spread of disease. Treatment for lung cancer is typically surgical, radiological or chemotherapy or combinations thereof, but usually with poor outcome due to the late diagnosis of disease.

The current tests for lung cancer lack either the clinical sensitivity to detect early tumors or provide inadequate stage/grade information or lack tumor specificity due to their originating from other tumor types or being present in benign lung disorders. There is therefore a need to develop specific tests that can improve lung cancer diagnosis and prognosis and potentially differentiate between NSCLC and SCLC. The present invention achieves these and other related objectives by providing methods that are useful for the identification of tissue-specific polynucleotides, in particular tumor-specific polynucleotides, as well as antibodies and methods, compositions and kits for the detection and monitoring of cancer cells in a patient afflicted with the disease.

SUMMARY OF THE INVENTION

The present invention provides methods for detecting the presence of lung cancer cells in a patient. Such methods comprise the steps of: (a) obtaining a biological sample from the patient; (b) contacting the biological sample with two or more oligonucleotide pairs specific for independent polynucleotide sequences which are unrelated to one another, wherein the oligonucleotide pairs hybridize, under moderately stringent conditions, to their respective polynucleotides and the complements thereof (c) amplifying the polynucleotides; and (d) detecting the amplified polynucleotides; wherein the presence of one or more of the amplified polynucleotides indicates the presence of lung cancer cells in the patient.

By some embodiments, detection of the amplified polynucleotides may be preceded by a fractionation step such as, for example, gel electrophoresis. Alternatively or additionally, detection of the amplified polynucleotides may be achieved by hybridization of a labeled oligonucleotide probe that hybridizes specifically, under moderately stringent conditions, to such polynucleotides. Oligonucleotide labeling may be achieved by incorporating a radiolabeled nucleotide or by incorporating a fluorescent label.

In certain preferred embodiments, cells of a specific tissue type may be enriched from the biological sample prior to the steps of detection. Enrichment may be achieved by a methodology selected from the group consisting of cell capture and cell depletion. Exemplary cell capture methods include immunocapture and comprise the steps of: (a) adsorbing an antibody to a tissue-specific cell surface to cells said biological sample; (b) separating the antibody adsorbed tissue-specific cells from the remainder of the biological sample. Exemplary cell depletion may be achieved by cross-linking red cells and white cells followed by a subsequent fractionation step to remove the cross-linked cells.xxx

Alternative embodiments of the present invention provide methods for determining the presence or absence of lung cancer in a patient, comprising the steps of: (a) contacting a biological sample obtained from the patient with two or more oligonucleotides that hybridize to two or more polynucleotides that encode two or more lung tumor proteins; (b) detecting in the sample a level of at least one of the polynucleotides (such as, for example,

mRNA) that hybridize to the oligonucleotides; and (c) comparing the level of polynucleotides that hybridize to the oligonucleotides with a predetermined cut-off value, and therefrom determining the presence or absence of lung cancer in the patient. Within certain embodiments, the amount of mRNA is detected via polymerase chain reaction using, for example, at least one oligonucleotide primer that hybridizes to a polynucleotide encoding a polypeptide as recited above, or a complement of such a polynucleotide. Within other embodiments, the amount of mRNA is detected using a hybridization technique, employing an oligonucleotide probe that hybridizes to a polynucleotide that encodes a polypeptide as recited above, or a complement of such a polynucleotide.

In related aspects, methods are provided for monitoring the progression of lung cancer in a patient, comprising the steps of: (a) contacting a biological sample obtained from a patient with two or more oligonucleotides that hybridize to two or more polynucleotides that encode lung tumor proteins; (b) detecting in the sample an amount of the polynucleotides that hybridize to the oligonucleotides; (c) repeating steps (a) and (b) using a biological sample obtained from the patient at a subsequent point in time; and (d) comparing the amount of polynucleotide detected in step (c) with the amount detected in step (b) and therefrom monitoring the progression of the cancer in the patient.

Certain embodiments of the present invention provide that the step of amplifying said first polynucleotide and said second polynucleotide is achieved by the polymerase chain reaction (PCR).

The present invention also provides kits that are suitable for performing the detection methods of the present invention. Exemplary kits comprise oligonucleotide primer pairs each one of which specifically hybridizes to a distinct polynucleotide. Within certain embodiments, kits according to the present invention may also comprise a nucleic acid polymerase and suitable buffer.

These and other aspects of the present invention will become apparent upon reference to the following detailed description and attached drawings. All references disclosed herein are hereby incorporated by reference in their entirety as if each was incorporated individually.

BRIEF DESCRIPTION OF SEQUENCE IDENTIFIERS

SEQ ID NO: 1 is the determined cDNA sequence L762P.

SEQ ID NO: 2 is the amino acid sequence encoded by the sequence of SEQ ID NO: 1.

SEQ ID NO: 3 is the determined cDNA sequence L984P.

SEQ ID NO: 4 is the amino acid sequence encoded by the sequence of SEQ ID NO: 3.

SEQ ID NO: 5 is the determined cDNA sequence L550S.

SEQ ID NO: 6 is the amino acid sequence encoded by the sequence of SEQ ID NO: 5.

SEQ ID NO: 7 is the determined cDNA sequence L552S.

SEQ ID NO: 8 is the amino acid sequence encoded by the sequence of SEQ ID NO: 7.

SEQ ID NO:9 is the DNA sequence of L552S INT forward primer.

SEQ ID NO:10 is the DNA sequence of L552S INT reverse primer.

SEQ ID NO:11 is the DNA sequence of L552S Taqman probe.

SEQ ID NO:12 is the DNA sequence of L550S INT forward primer.

SEQ ID NO:13 is the DNA sequence of L550S INT reverse primer.

SEQ ID NO:14 is the DNA sequence of L550S Taqman probe.

SEQ ID NO:15 is the DNA sequence of L726P INT forward primer.

SEQ ID NO:16 is the DNA sequence of L726P INT reverse primer.

SEQ ID NO:17 is the DNA sequence of L726P Taqman probe.

SEQ ID NO:18 is the DNA sequence of L984P INT forward primer.

SEQ ID NO:19 is the DNA sequence of L984P INT reverse primer.

SEQ ID NO:20 is the DNA sequence of L984P Taqman probe.

SEQ ID NO:21 is the determined cDNA sequence of L763P.

SEQ ID NO:22 is the amino acid sequence encoded by the sequence of SEQ ID NO:21.

SEQ ID NO:23 is the DNA sequence of L763P INT forward primer.

SEQ ID NO:24 is the DNA sequence of L763P reverse primer.

SEQ ID NO:25 is the DNA sequence of L763P Taqman probe.

SEQ ID NO:26 is the determined cDNA sequence of L587.

SEQ ID NO:27 is the amino acid sequence encoded by the sequence of SEQ ID NO:26.

SEQ ID NO:28 is the DNA sequence of L587 INT forward primer.

SEQ ID NO:29 is the DNA sequence of L587 INT reverse primer.

SEQ ID NO:30 is the DNA sequence of L587 Taqman probe.

SEQ ID NO:31 is the determined cDNA sequence of L523.

SEQ ID NO:32 is the amino acid sequence encoded by the sequence of SEQ ID NO:31.

SEQ ID NO:33 is the DNA sequence of L523 primer.

SEQ ID NO:34 is the DNA sequence of L523 primer.

DETAILED DESCRIPTION OF THE INVENTION

As noted above, the present invention is directed generally to methods that are suitable for the identification of tissue-specific polynucleotides as well as to methods, compositions and kits that are suitable for the diagnosis and monitoring of lung cancer, in particular such methods, compositions and kits are suitable for use in the diagnosis, differentiation and/or prognosis of NSCLC and SCLC. Such diagnostic methods will form the basis for a molecular diagnostic test for detecting lung cancer metastases in lung tissue and for the detection of anchorage independent lung cancer cells in blood as well as in mediastinal lymph nodes of distant metastases.

A variety of genes have been identified as over-expressed in lung tumors, in particular squamous or adeno forms of NSCLC or small cell carcinomas. These include, but are not limited to: L762P, L984P, L550S/L548S, L552S/L547S, L552/L547S, L200T, L514S, L551S, L587S, L763S, L773P, L801P. L985P, L1058C, L1081C, L523S, OF1783P, B307D (WIPO International Patent Application Nos: WO 99/47674, published September 23, 1999; WO 00/61612, published October 19, 2000; WO 02/00174, published January 3, 2002; WO 02/47534, published June 20, 2002; WO 01/72295, published October 4, 2001; WO 02/092001, published November 21, 2002; WO 01/00828, published January 1, 2001; WO 02/04514, published January 17, 2002; WO 01/92525, published December 6, 2002; WO 02/02623, published January 10, 2002. US Patent Nos: Wang et al., 6,482,597, issued November 22, 2002; Wang et al., 6,518,256, issued February 11, 2003; Wang et al., 6,426,072, issued July 30, 2002; Reed et al., 6,210,883, issued April 3, 2001; Wang et al., 6,504,010, issued January 7, 2003; Wang et al., 6,509,448, issued

January 21, 2003. Wang *et al; Oncogene*; *21*(49):7598-604, 2002 (collagen type XI alpha 1).).

These genes were identified and characterized using PCR and cDNA library subtractions as well as electronic subtractions with each of the tumor types individually. The cDNAs identified were then evaluated by microarray then by Real Time PCR on tissue panels to identify specific expression patterns. Table 1 highlights the specificity of these genes for either adeno or squamous forms of NSCLC or both as well as genes specific for small cell lung carcinomas. In some cases reactivity with large cell carcinomas has also been identified by Real Time PCR analysis.

Table 1

Gene	Squamous	Adeno	Small cell	Large cell	Normal Lung
L762P	+++++	+			-
L984P		+	+++		-
L550S/L548S		+++++	+		-
L552S/L547S	++	+++++			-
L200T	+	++		++	-
L514S	++++	++++			-
L551S		++++		+/-	-
L587S	+	+	+++	+	-
L763P	+++++				-
L773P	+++	+++			-
L801P	++++	++++		++	-
L978P	+	++	+++++	+/-	-
L985P		+	+++++		-
L1058C			++		-
L1081C			++		-
L523S	+++++	+++++	+	++	-
OF 1783P			+++++		-
B307D	++	++		+	-

Identification of Tissue-specific Polynucleotides

Certain embodiments of the present invention provide methods, compositions and kits for the detection of lung cancer cells within a biological sample from patients with different type, stage and grade of tumors. These methods comprise the step of detecting

one or more tissue-specific polynucleotide(s) from a patient's biological sample the over-expression of which polynucleotides indicates the presence of lung cancer cells within the patient's biological sample. Accordingly, the present invention also provides methods that are suitable for the identification of tissue-specific polynucleotides. As used herein, the phrases "tissue-specific polynucleotides" or "tumor-specific polynucleotides" are meant to include all polynucleotides that are at least two-fold over-expressed as compared to one or more control tissues. As discussed in further detail herein below, over-expression of a given polynucleotide may be assessed, for example, by microarray and/or quantitative real-time polymerase chain reaction (Real-time PCR™) methodologies.

Exemplary methods for detecting tissue-specific polynucleotides may comprise the steps of: (a) performing a genetic subtraction to identify a pool of polynucleotides from a tissue of interest; (b) performing a DNA microarray analysis to identify a first subset of said pool of polynucleotides of interest wherein each member polynucleotide of said first subset is at least two-fold over-expressed in said tissue of interest as compared to a control tissue; and (c) performing a quantitative polymerase chain reaction analysis on polynucleotides within said first subset to identify a second subset of polynucleotides that are at least two-fold over-expressed as compared to said control tissue.

Polynucleotides Generally

As used herein, the term "polynucleotide" refers generally to either DNA or RNA molecules. Polynucleotides may be naturally occurring as normally found in a biological sample such as blood, serum, lymph node, bone marrow, sputum, urine and tumor biopsy samples. Alternatively, polynucleotides may be derived synthetically by, for example, a nucleic acid polymerization reaction. As will be recognized by the skilled artisan, polynucleotides may be single-stranded (coding or antisense) or double-stranded, and may be DNA (genomic, cDNA or synthetic) or RNA molecules. RNA molecules include HnRNA molecules, which contain introns and correspond to a DNA molecule in a one-to-one manner, and mRNA molecules, which do not contain introns. Additional coding or non-coding sequences may, but need not, be present within a polynucleotide of the present

invention, and a polynucleotide may, but need not, be linked to other molecules and/or support materials.

Polynucleotides may comprise a native sequence (*i.e.* an endogenous sequence that encodes a tumor protein, such as a lung tumor protein, or a portion thereof) or may comprise a variant, or a biological or antigenic functional equivalent of such a sequence. Polynucleotide variants may contain one or more substitutions, additions, deletions and/or insertions, as further described below. The term "variants" also encompasses homologous genes of xenogenic origin.

When comparing polynucleotide or polypeptide sequences, two sequences are said to be "identical" if the sequence of nucleotides or amino acids in the two sequences is the same when aligned for maximum correspondence, as described below. Comparisons between two sequences are typically performed by comparing the sequences over a comparison window to identify and compare local regions of sequence similarity. A "comparison window" as used herein, refers to a segment of at least about 20 contiguous positions, usually 30 to about 75, 40 to about 50, in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned.

Optimal alignment of sequences for comparison may be conducted using the Megalign program in the Lasergene suite of bioinformatics software (DNASTAR, Inc., Madison, WI), using default parameters. This program embodies several alignment schemes described in the following references: Dayhoff, M.O. (1978) A model of evolutionary change in proteins – Matrices for detecting distant relationships. In Dayhoff, M.O. (ed.) Atlas of Protein Sequence and Structure, National Biomedical Research Foundation, Washington DC Vol. 5, Suppl. 3, pp. 345-358; Hein J. (1990) Unified Approach to Alignment and Phylogenes pp. 626-645 *Methods in Enzymology* vol. 183, Academic Press, Inc., San Diego, CA; Higgins, D.G. and Sharp, P.M. (1989) *CABIOS* 5:151-153; Myers, E.W. and Muller W. (1988) *CABIOS* 4:11-17; Robinson, E.D. (1971) *Comb. Theor 11*:105; Santou, N. Nes, M. (1987) *Mol. Biol. Evol.* 4:406-425; Sneath, P.H.A. and Sokal, R.R. (1973) *Numerical Taxonomy – the Principles and Practice of*

Numerical Taxonomy, Freeman Press, San Francisco, CA; Wilbur, W.J. and Lipman, D.J. (1983) *Proc. Natl. Acad., Sci. USA 80*:726-730.

Alternatively, optimal alignment of sequences for comparison may be conducted by the local identity algorithm of Smith and Waterman (1981) *Add. APL. Math* 2:482, by the identity alignment algorithm of Needleman and Wunsch (1970) *J. Mol. Biol.* 48:443, by the search for similarity methods of Pearson and Lipman (1988) *Proc. Natl. Acad. Sci. USA* 85: 2444, by computerized implementations of these algorithms (GAP, BESTFIT, BLAST, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group (GCG), 575 Science Dr., Madison, WI), or by inspection.

One preferred example of algorithms that are suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul *et al.* (1977) *Nucl. Acids Res.* 25:3389-3402 and Altschul *et al.* (1990) *J. Mol. Biol.* 215:403-410, respectively. BLAST and BLAST 2.0 can be used, for example with the parameters described herein, to determine percent sequence identity for the polynucleotides and polypeptides of the invention. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information. In one illustrative example, cumulative scores can be calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always >0) and N (penalty score for mismatching residues; always <0). For amino acid sequences, a scoring matrix can be used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a wordlength (W) of 11, and expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff and Henikoff (1989) *Proc. Natl. Acad. Sci. USA* 89:10915) alignments, (B) of 50, expectation (E) of 10, M=5, N=-4 and a comparison of both strands.

Preferably, the "percentage of sequence identity" is determined by comparing two optimally aligned sequences over a window of comparison of at least 20 positions, wherein the portion of the polynucleotide or polypeptide sequence in the comparison window may comprise additions or deletions (*i.e.*, gaps) of 20 percent or less, usually 5 to 15 percent, or 10 to 12 percent, as compared to the reference sequences (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid bases or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the reference sequence (*i.e.*, the window size) and multiplying the results by 100 to yield the percentage of sequence identity.

Therefore, the present invention encompasses polynucleotide and polypeptide sequences having substantial identity to the sequences disclosed herein, for example those comprising at least 50% sequence identity, preferably at least 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% or higher, sequence identity compared to a polynucleotide or polypeptide sequence of this invention using the methods described herein, (*e.g.*, BLAST analysis using standard parameters, as described below). One skilled in this art will recognize that these values can be appropriately adjusted to determine corresponding identity of proteins encoded by two nucleotide sequences by taking into account codon degeneracy, amino acid similarity, reading frame positioning and the like.

In additional embodiments, the present invention provides isolated polynucleotides and polypeptides comprising various lengths of contiguous stretches of sequence identical to or complementary to one or more of the sequences disclosed herein. For example, polynucleotides are provided by this invention that comprise at least about 15, 20, 30, 40, 50, 75, 100, 150, 200, 300, 400, 500 or 1000 or more contiguous nucleotides of one or more of the sequences disclosed herein as well as all intermediate lengths there between. It will be readily understood that "intermediate lengths", in this context, means any length between the quoted values, such as 16, 17, 18, 19, *etc.*; 21, 22, 23, *etc.*; 30, 31, 32, *etc.*; 50,

51, 52, 53, *etc.*; 100, 101, 102, 103, *etc.*; 150, 151, 152, 153, *etc.*; including all integers through 200-500; 500-1,000, and the like.

The polynucleotides of the present invention, or fragments thereof, regardless of the length of the coding sequence itself, may be combined with other DNA sequences, such as promoters, polyadenylation signals, additional restriction enzyme sites, multiple cloning sites, other coding segments, and the like, such that their overall length may vary considerably. It is therefore contemplated that a nucleic acid fragment of almost any length may be employed, with the total length preferably being limited by the ease of preparation and use in the intended recombinant DNA protocol. For example, illustrative DNA segments with total lengths of about 10,000, about 5000, about 3000, about 2,000, about 1,000, about 500, about 200, about 100, about 50 base pairs in length, and the like, (including all intermediate lengths) are contemplated to be useful in many implementations of this invention.

In other embodiments, the present invention is directed to polynucleotides that are capable of hybridizing under moderately stringent conditions to a polynucleotide sequence provided herein, or a fragment thereof, or a complementary sequence thereof. Hybridization techniques are well known in the art of molecular biology. For purposes of illustration, suitable moderately stringent conditions for testing the hybridization of a polynucleotide of this invention with other polynucleotides include prewashing in a solution of 5 X SSC, 0.5% SDS, 1.0 mM EDTA (pH 8.0); hybridizing at 50°C-65°C, 5 X SSC, overnight; followed by washing twice at 65°C for 20 minutes with each of 2X, 0.5X and 0.2X SSC containing 0.1% SDS.

Moreover, it will be appreciated by those of ordinary skill in the art that, as a result of the degeneracy of the genetic code, there are many nucleotide sequences that encode a polypeptide as described herein. Some of these polynucleotides bear minimal homology to the nucleotide sequence of any native gene. Nonetheless, polynucleotides that vary due to differences in codon usage are specifically contemplated by the present invention. Further, alleles of the genes comprising the polynucleotide sequences provided herein are within the scope of the present invention. Alleles are endogenous genes that are altered as a result of

one or more mutations, such as deletions, additions and/or substitutions of nucleotides. The resulting mRNA and protein may, but need not, have an altered structure or function. Alleles may be identified using standard techniques (such as hybridization, amplification and/or database sequence comparison).

Microarray Analyses

Polynucleotides that are suitable for detection according to the methods of the present invention may be identified, as described in more detail below, by screening a microarray of cDNAs for tissue and/or tumor-associated expression (*e.g.*, expression that is at least two-fold greater in a tumor than in normal tissue, as determined using a representative assay provided herein). Such screens may be performed, for example, using a Synteni microarray (Palo Alto, CA) according to the manufacturer's instructions (and essentially as described by Schena *et al.*, *Proc. Natl. Acad. Sci. USA* 93:10614-10619 (1996) and Heller *et al.*, *Proc. Natl. Acad. Sci. USA* 94:2150-2155 (1997)).

Microarray is an effective method for evaluating large numbers of genes but due to its limited sensitivity it may not accurately determine the absolute tissue distribution of low abundance genes or may underestimate the degree of overexpression of more abundant genes due to signal saturation. For those genes showing overexpression by microarray expression profiling, further analysis was performed using quantitative RT-PCR based on Taqman™ probe detection, which comprises a greater dynamic range of sensitivity. Several different panels of normal and tumor tissues, distant metastases and cell lines were used for this purpose.

Quantitative Real-time Polymerase Chain Reaction

Suitable polynucleotides according to the present invention may be further characterized or, alternatively, originally identified by employing a quantitative PCR methodology such as, for example, the Real-time PCR methodology. By this methodology, tissue and/or tumor samples, such as, *e.g.*, metastatic tumor samples, may be tested along side, the corresponding normal tissue sample and/or a panel of unrelated normal tissue samples.

Real-time PCR (*see* Gibson et al., *Genome Research* 6:995-1001, 1996; Heid et al., *Genome Research* 6:986-994, 1996) is a technique that evaluates the level of PCR product accumulation during amplification. This technique permits quantitative evaluation of mRNA levels in multiple samples. Briefly, mRNA is extracted from tumor and normal tissue and cDNA is prepared using standard techniques.

Real-time PCR may, for example, be performed either on the ABI 7700 Prism or on a GeneAmp® 5700 sequence detection system (Applied Biosystems, Foster City, CA). The 7700 system uses a forward and a reverse primer in combination with a specific probe with a 5' fluorescent reporter dye at one end and a 3' quencher dye at the other end (Taqman™). When the Real-time PCR is performed using Taq DNA polymerase with 5'-3' nuclease activity, the probe is cleaved and begins to fluoresce allowing the reaction to be monitored by the increase in fluorescence (Real-time). The 5700 system uses SYBR® green, a fluorescent dye, that only binds to double stranded DNA, and the same forward and reverse primers as the 7700 instrument. Matching primers and fluorescent probes may be designed according to the primer express program (Applied Biosystems, Foster City, CA). Optimal concentrations of primers and probes are initially determined by those of ordinary skill in the art. Control (*e.g.*, β-actin) primers and probes may be obtained commercially from, for example, Perkin Elmer/Applied Biosystems (Foster City, CA).

To quantitate the amount of specific RNA in a sample, a standard curve is generated using a plasmid containing the gene of interest. Standard curves are generated using the Ct values determined in the real-time PCR, which are related to the initial cDNA concentration used in the assay. Standard dilutions ranging from 10-10^6 copies of the gene of interest are generally sufficient. In addition, a standard curve is generated for the control sequence. This permits standardization of initial RNA content of a tissue sample to the amount of control for comparison purposes.

In accordance with the above, and as described further below, the present invention provides the illustrative lung tissue- and/or tumor-specific polynucleotides L552S, L550S, L762P, L984P, L763P and L587 having sequences set forth in SEQ ID NOs: 1, 3, 5, 7, 21 and 26, illustrative polypeptides encoded thereby having amino acid sequences set forth in

SEQ ID NO: 2, 4, 6, 8, 22 and 27 that may be suitably employed in the detection of cancer, more specifically, lung cancer.

Methodologies for the Detection of Cancer

In general, a cancer cell may be detected in a patient based on the presence of one or more polynucleotides within cells of a biological sample (for example, blood, lymph nodes, bone marrow, sera, sputum, urine and/or tumor biopsies) obtained from the patient. In other words, such polynucleotides may be used as markers to indicate the presence or absence of a cancer such as, *e.g.*, lung cancer.

As discussed in further detail herein, the present invention achieves these and other related objectives by providing a methodology for the simultaneous detection of more than one polynucleotide, the presence of which is diagnostic of the presence of lung cancer cells in a biological sample. Each of the various cancer detection methodologies disclosed herein have in common a step of hybridizing one or more oligonucleotide primers and/or probes, the hybridization of which is demonstrative of the presence of a tumor- and/or tissue-specific polynucleotide. Depending on the precise application contemplated, it may be preferred to employ one or more intron-spanning oligonucleotides that are inoperative against polynucleotide of genomic DNA and, thus, these oligonucleotides are effective in substantially reducing and/or eliminating the detection of genomic DNA in the biological sample.

Further disclosed herein are methods for enhancing the sensitivity of these detection methodologies by subjecting the biological samples to be tested to one or more cell capture and/or cell depletion methodologies.

By certain embodiments of the present invention, the presence of lung cancer cell in a patient may be determined by employing the following steps: (a) contacting a biological sample obtained from the patient with two or more oligonucleotides that hybridize to two or more polynucleotides that encode two or more lung tumor proteins as described herein; (b) detecting in the sample a level of at least one of the polynucleotides (such as, for example, mRNA) that hybridize to the oligonucleotides; and (c) comparing the level of

polynucleotides that hybridize to the oligonucleotides with a predetermined cut-off value, and therefrom determining the presence or absence of lung cancer in the patient.

To permit hybridization under assay conditions, oligonucleotide primers and probes should comprise an oligonucleotide sequence that has at least about 60%, preferably at least about 75% and more preferably at least about 90%, identity to a portion of a polynucleotide encoding a lung tumor protein that is at least 10 nucleotides, and preferably at least 20 nucleotides, in length. Preferably, oligonucleotide primers hybridize to a polynucleotide encoding a polypeptide described herein under moderately stringent conditions, as defined above. Oligonucleotide primers which may be usefully employed in the diagnostic methods described herein preferably are at least 10-40 nucleotides in length. In a preferred embodiment, the oligonucleotide primers comprise at least 10 contiguous nucleotides, more preferably at least 15 contiguous nucleotides, of a DNA molecule having a sequence recited in SEQ ID NO: 1, 3, 5 or 7. Techniques for both PCR based assays and hybridization assays are well known in the art (*see*, for example, Mullis *et al.*, *Cold Spring Harbor Symp. Quant. Biol.*, *51*:263, 1987; Erlich ed., *PCR Technology*, Stockton Press, NY, 1989).

The present invention also provides amplification-based methods for detecting the presence of lung cancer cells in a patient. Exemplary methods comprise the steps of (a) obtaining a biological sample from the patient; (b) contacting the biological sample with two or more oligonucleotide pairs specific for independent polynucleotide sequences which are unrelated to one another, wherein the oligonucleotide pairs hybridize, under moderately stringent conditions, to their respective polynucleotides and the complements thereof (c) amplifying the polynucleotides; and (d) detecting the amplified polynucleotides; wherein the presence of one or more of the amplified polynucleotides indicates the presence of lung cancer cells in the patient.

Methods according to the present invention are suitable for identifying polynucleotides obtained from a wide variety of biological sample such as, for example, blood, serum, lymph node, bone marrow, sputum, urine and tumor biopsy sample, among others.

Certain exemplary embodiments of the present invention provide methods wherein the polynucleotides to be detected are selected from the group consisting of L762, L984, L550, L552, L763 and L587. Alternatively and/or additionally, polynucleotides to be detected may be selected from the group consisting of those depicted in SEQ ID NOs: 1, 3, 5, 7, 21 and 26.

Suitable exemplary oligonucleotide probes and/or primers that may be used according to the methods of the present invention are disclosed herein. In certain preferred embodiments that eliminate the background detection of genomic DNA, the oligonucleotides may be intron spanning oligonucleotides.

Depending on the precise application contemplated, the artisan may prefer to detect the tissue- and/or tumor-specific polynucleotides by detecting a radiolabel and detecting a fluorophore. More specifically, the oligonucleotide probe and/or primer may comprises a detectable moiety such as, for example, a radiolabel and/or a fluorophore.

Alternatively or additionally, methods of the present invention may also comprise a step of fractionation prior to detection of the tissue- and/or tumor-specific polynucleotides such as, for example, by gel electrophoresis.

In other embodiments, methods described herein may be used as to monitor the progression of cancer. By these embodiments, assays as provided for the diagnosis of lung cancer may be performed over time, and the change in the level of reactive polypeptide(s) or polynucleotide(s) evaluated. For example, the assays may be performed every 24-72 hours for a period of 6 months to 1 year, and thereafter performed as needed. In general, a cancer is progressing in those patients in whom the level of polypeptide or polynucleotide detected increases over time. In contrast, the cancer is not progressing when the level of reactive polypeptide or polynucleotide either remains constant or decreases with time.

Certain *in vivo* diagnostic assays may be performed directly on a tumor. One such assay involves contacting tumor cells with a binding agent. The bound binding agent may then be detected directly or indirectly via a reporter group. Such binding agents may also be used in histological applications. Alternatively, polynucleotide probes may be used within such applications.

As noted above, to improve sensitivity, multiple lung tumor protein markers may be assayed within a given sample. It will be apparent that binding agents specific for different proteins provided herein may be combined within a single assay. Further, multiple primers or probes may be used concurrently. The selection of tumor protein markers may be based on routine experiments to determine combinations that results in optimal sensitivity. In addition, or alternatively, assays for tumor proteins provided herein may be combined with assays for other known tumor antigens.

Cell Enrichment

In other aspects of the present invention, cell capture technologies may be used prior to polynucleotide detection to improve the sensitivity of the various detection methodologies disclosed herein.

Exemplary cell enrichment methodologies employ immunomagnetic beads that are coated with specific monoclonal antibodies to surface cell markers, or tetrameric antibody complexes, may be used to first enrich or positively select cancer cells in a sample. Various commercially available kits may be used, including Dynabeads® Epithelial Enrich (Dynal Biotech, Oslo, Norway), StemSep™ (StemCell Technologies, Inc., Vancouver, BC), and RosetteSep (StemCell Technologies). The skilled artisan will recognize that other readily available methodologies and kits may also be suitably employed to enrich or positively select desired cell populations.

Dynabeads® Epithelial Enrich contains magnetic beads coated with mAbs specific for two glycoprotein membrane antigens expressed on normal and neoplastic epithelial tissues. The coated beads may be added to a sample and the sample then applied to a magnet, thereby capturing the cells bound to the beads. The unwanted cells are washed away and the magnetically isolated cells eluted from the beads and used in further analyses.

RosetteSep can be used to enrich cells directly from a blood sample and consists of a cocktail of tetrameric antibodies that target a variety of unwanted cells and crosslinks them to glycophorin A on red blood cells (RBC) present in the sample, forming rosettes. When centrifuged over Ficoll, targeted cells pellet along with the free RBC.

The combination of antibodies in the depletion cocktail determines which cells will be removed and consequently which cells will be recovered. Antibodies that are available include, but are not limited to: CD2, CD3, CD4, CD5, CD8, CD10, CD11b, CD14, CD15, CD16, CD19, CD20, CD24, CD25, CD29, CD33, CD34, CD36, CD38, CD41, CD45, CD45RA, CD45RO, CD56, CD66B, CD66e, HLA-DR, IgE, and TCR$\alpha\beta$. Additionally, it is contemplated in the present invention that mAbs specific for lung tumor antigens, can be developed and used in a similar manner. For example, mAbs that bind to tumor-specific cell surface antigens may be conjugated to magnetic beads, or formulated in a tetrameric antibody complex, and used to enrich or positively select metastatic lung tumor cells from a sample. Such a system can be used to evaluate blood samples from different forms of lung cancers, in particular adneo and squamous forms of NSCLC and small cell carcinomas for the presence of circulating tumor cells using the inventive multiplex PCR assay as described herein.

Once a sample is enriched or positively selected, cells may be further analyzed. For example, the cells may be lysed and RNA isolated. RNA may then be subjected to RT-PCR analysis using lung tumor-specific multiplex primers in a Real-time PCR assay as described herein.

In another aspect of the present invention, cell capture technologies may be used in conjunction with Real-Time PCR to provide a more sensitive tool for detection of metastatic cells expressing lung tumor antigens.

Yet another method that may be employed is an anti-ganglioside G_{M1}/G_{M1} cell capture antibody system. Gangliosides are cell membrane bound glycosphingolipids, several species of which have been shown to be over-expressed on the cell surface of most cancers of neuroectodermal and epithelial origin, in particular lung cancer. Cell surface expression of G_{M2} is seen in several types of lung cancer, particularly in SCLC which make it an attractive target for a monoclonal antibody based lung cancer immunotherapy and also for use as a capture method in conjunction with G_{M1}.

Probes and Primers

As noted above and as described in further detail herein, certain methods, compositions and kits according to the present invention utilize two or more oligonucleotide primer pairs for the detection of lung cancer. The ability of such nucleic acid probes to specifically hybridize to a sequence of interest will enable them to be of use in detecting the presence of complementary sequences in a biological sample.

Alternatively, in other embodiments, the probes and/or primers of the present invention may be employed for detection via nucleic acid hybridization. As such, it is contemplated that nucleic acid segments that comprise a sequence region of at least about 15 nucleotide long contiguous sequence that has the same sequence as, or is complementary to, a 15 nucleotide long contiguous sequence of a polynucleotide to be detected will find particular utility. Longer contiguous identical or complementary sequences, *e.g.*, those of about 20, 30, 40, 50, 100, 200, 500, 1000 (including all intermediate lengths) and even up to full length sequences will also be of use in certain embodiments.

Oligonucleotide primers having sequence regions consisting of contiguous nucleotide stretches of 10-14, 15-20, 30, 50, or even of 100-200 nucleotides or so (including intermediate lengths as well), identical or complementary to a polynucleotide to be detected, are particularly contemplated as primers for use in amplification reactions such as, *e.g.*, the polymerase chain reaction (PCR™). This would allow a polynucleotide to be analyzed, both in diverse biological samples such as, for example, blood, lymph nodes and bone marrow.

The use of a primer of about 15-25 nucleotides in length allows the formation of a duplex molecule that is both stable and selective. Molecules having contiguous complementary sequences over stretches greater than 15 bases in length are generally preferred, though, in order to increase stability and selectivity of the hybrid, and thereby improve the quality and degree of specific hybrid molecules obtained. One will generally prefer to design primers having gene-complementary stretches of 15 to 25 contiguous nucleotides, or even longer where desired.

Primers may be selected from any portion of the polynucleotide to be detected. All that is required is to review the sequence, such as those exemplary polynucleotides set forth herein or to any continuous portion of the sequence, from about 15-25 nucleotides in length up to and including the full length sequence, that one wishes to utilize as a primer. The choice of primer sequences may be governed by various factors. For example, one may wish to employ primers from towards the termini of the total sequence. The exemplary primers disclosed herein may optionally be used for their ability to selectively form duplex molecules with complementary stretches of the entire polynucleotide of interest such as those set forth SEQ ID NOs: 1, 3 ,5, 7, 21 and 26.

The present invention further provides the nucleotide sequence of various exemplary oligonucleotide primers and probes, that may be used, as described in further detail herein, according to the methods of the present invention for the detection of cancer.

Oligonucleotide primers according to the present invention may be readily prepared routinely by methods commonly available to the skilled artisan including, for example, directly synthesizing the primers by chemical means, as is commonly practiced using an automated oligonucleotide synthesizer. Depending on the application envisioned, one will typically desire to employ varying conditions of hybridization to achieve varying degrees of selectivity of probe towards target sequence. For applications requiring high selectivity, one will typically desire to employ relatively stringent conditions to form the hybrids, *e.g.*, one will select relatively low salt and/or high temperature conditions, such as provided by a salt concentration of from about 0.02 M to about 0.15 M salt at temperatures of from about 50°C to about 70°C. Such selective conditions tolerate little, if any, mismatch between the probe and the template or target strand, and would be particularly suitable for isolating related sequences.

Polynucleotide Amplification Techniques

Each of the specific embodiments outlined herein for the detection of lung cancer has in common the detection of a tissue- and/or tumor-specific polynucleotide via the hybridization of one or more oligonucleotide primers and/or probes. Depending on such factors as the relative number of cancer cells present in the biological sample and/or the

level of polynucleotide expression within each lung cancer cell, it may be preferred to perform an amplification step prior to performing the steps of detection. For example, at least two oligonucleotide primers may be employed in a polymerase chain reaction (PCR) based assay to amplify a portion of a lung tumor cDNA derived from a biological sample, wherein at least one of the oligonucleotide primers is specific for (*i.e.*, hybridizes to) a polynucleotide encoding the lung tumor protein. The amplified cDNA may optionally be subjected to a fractionation step such as, for example, gel electrophoresis.

A number of template dependent processes are available to amplify the target sequences of interest present in a sample. One of the best known amplification methods is the polymerase chain reaction (PCR™) which is described in detail in U.S. Patent Nos. 4,683,195, 4,683,202 and 4,800,159. Briefly, in PCR™, two primer sequences are prepared which are complementary to regions on opposite complementary strands of the target sequence. An excess of deoxynucleoside triphosphates is added to a reaction mixture along with a DNA polymerase (*e.g.*, *Taq* polymerase). If the target sequence is present in a sample, the primers will bind to the target and the polymerase will cause the primers to be extended along the target sequence by adding on nucleotides. By raising and lowering the temperature of the reaction mixture, the extended primers will dissociate from the target to form reaction products, excess primers will bind to the target and to the reaction product and the process is repeated. Preferably reverse transcription and PCR™ amplification procedure may be performed in order to quantify the amount of mRNA amplified. Polymerase chain reaction methodologies are well known in the art.

One preferred methodology for polynucleotide amplification employs RT-PCR, in which PCR is applied in conjunction with reverse transcription. Typically, RNA is extracted from a biological sample, such as blood, serum, lymph node, bone marrow, sputum, urine and tumor biopsy samples, and is reverse transcribed to produce cDNA molecules. PCR amplification using at least one specific primer generates a cDNA molecule, which may be separated and visualized using, for example, gel electrophoresis. Amplification may be performed on biological samples taken from a patient and from an individual who is not afflicted with a cancer. The amplification reaction may be performed

on several dilutions of cDNA spanning two orders of magnitude. A two-fold or greater increase in expression in several dilutions of the test patient sample as compared to the same dilutions of the non-cancerous sample is typically considered positive.

Any of a variety of commercially available kits may be used to perform the amplification step. One such amplification technique is inverse PCR (*see* Triglia *et al.*, *Nucl. Acids Res. 16*:8186, 1988), which uses restriction enzymes to generate a fragment in the known region of the gene. The fragment is then circularized by intramolecular ligation and used as a template for PCR with divergent primers derived from the known region. Within an alternative approach, sequences adjacent to a partial sequence may be retrieved by amplification with a primer to a linker sequence and a primer specific to a known region. The amplified sequences are typically subjected to a second round of amplification with the same linker primer and a second primer specific to the known region. A variation on this procedure, which employs two primers that initiate extension in opposite directions from the known sequence, is described in WIPO International Patent Application No.: WO 96/38591. Another such technique is known as "rapid amplification of cDNA ends" or RACE. This technique involves the use of an internal primer and an external primer, which hybridizes to a polyA region or vector sequence, to identify sequences that are 5' and 3' of a known sequence. Additional techniques include capture PCR (Lagerstrom *et al.*, *PCR Methods Applic. 1*:111-19, 1991) and walking PCR (Parker *et al.*, *Nucl. Acids. Res. 19*:3055-60, 1991). Other methods employing amplification may also be employed to obtain a full length cDNA sequence.

Another method for amplification is the ligase chain reaction (referred to as LCR), disclosed in Eur. Pat. Appl. Publ. No. 320,308. In LCR, two complementary probe pairs are prepared, and in the presence of the target sequence, each pair will bind to opposite complementary strands of the target such that they abut. In the presence of a ligase, the two probe pairs will link to form a single unit. By temperature cycling, as in PCR™, bound ligated units dissociate from the target and then serve as "target sequences" for ligation of excess probe pairs. U.S. Patent No. 4,883,750, describes an alternative method of amplification similar to LCR for binding probe pairs to a target sequence.

Qbeta Replicase, described in PCT Intl. Pat. Appl. Publ. No. PCT/US87/00880, may also be used as still another amplification method in the present invention. In this method, a replicative sequence of RNA that has a region complementary to that of a target is added to a sample in the presence of an RNA polymerase. The polymerase will copy the replicative sequence that can then be detected.

An isothermal amplification method, in which restriction endonucleases and ligases are used to achieve the amplification of target molecules that contain nucleotide 5'-[α-thio]triphosphates in one strand of a restriction site (Walker *et al.*, 1992), may also be useful in the amplification of nucleic acids in the present invention.

Strand Displacement Amplification (SDA) is another method of carrying out isothermal amplification of nucleic acids which involves multiple rounds of strand displacement and synthesis, *i.e.* nick translation. A similar method, called Repair Chain Reaction (RCR) is another method of amplification which may be useful in the present invention and is involves annealing several probes throughout a region targeted for amplification, followed by a repair reaction in which only two of the four bases are present. The other two bases can be added as biotinylated derivatives for easy detection. A similar approach is used in SDA.

Sequences can also be detected using a cyclic probe reaction (CPR). In CPR, a probe having a 3' and 5' sequences of non-target DNA and an internal or "middle" sequence of the target protein specific RNA is hybridized to DNA which is present in a sample. Upon hybridization, the reaction is treated with RNaseH, and the products of the probe are identified as distinctive products by generating a signal that is released after digestion. The original template is annealed to another cycling probe and the reaction is repeated. Thus, CPR involves amplifying a signal generated by hybridization of a probe to a target gene specific expressed nucleic acid.

Still other amplification methods described in Great Britain Pat. Appl. No. 2 202 328, and in PCT Intl. Pat. Appl. Publ. No. PCT/US89/01025, may be used in accordance with the present invention. In the former application, "modified" primers are used in a PCR-like, template and enzyme dependent synthesis. The primers may be modified by

labeling with a capture moiety (*e.g.*, biotin) and/or a detector moiety (*e.g.*, enzyme). In the latter application, an excess of labeled probes is added to a sample. In the presence of the target sequence, the probe binds and is cleaved catalytically. After cleavage, the target sequence is released intact to be bound by excess probe. Cleavage of the labeled probe signals the presence of the target sequence.

Other nucleic acid amplification procedures include transcription-based amplification systems (TAS) (Kwoh *et al.*, 1989; PCT Intl. Pat. Appl. Publ. No. WO 88/10315), including nucleic acid sequence based amplification (NASBA) and 3SR. In NASBA, the nucleic acids can be prepared for amplification by standard phenol/chloroform extraction, heat denaturation of a sample, treatment with lysis buffer and minispin columns for isolation of DNA and RNA or guanidinium chloride extraction of RNA. These amplification techniques involve annealing a primer that has sequences specific to the target sequence. Following polymerization, DNA/RNA hybrids are digested with RNase H while double stranded DNA molecules are heat-denatured again. In either case the single stranded DNA is made fully double stranded by addition of second target-specific primer, followed by polymerization. The double stranded DNA molecules are then multiply transcribed by a polymerase such as T7 or SP6. In an isothermal cyclic reaction, the RNAs are reverse transcribed into DNA, and transcribed once again with a polymerase such as T7 or SP6. The resulting products, whether truncated or complete, indicate target-specific sequences.

Eur. Pat. Appl. Publ. No. 329,822, disclose a nucleic acid amplification process involving cyclically synthesizing single-stranded RNA ("ssRNA"), ssDNA, and double-stranded DNA (dsDNA), which may be used in accordance with the present invention. The ssRNA is a first template for a first primer oligonucleotide, which is elongated by reverse transcriptase (RNA-dependent DNA polymerase). The RNA is then removed from resulting DNA:RNA duplex by the action of ribonuclease H (RNase H, an RNase specific for RNA in a duplex with either DNA or RNA). The resultant ssDNA is a second template for a second primer, which also includes the sequences of an RNA polymerase promoter (exemplified by T7 RNA polymerase) 5' to its homology to its

template. This primer is then extended by DNA polymerase (exemplified by the large "Klenow" fragment of *E. coli* DNA polymerase I), resulting as a double-stranded DNA ("dsDNA") molecule, having a sequence identical to that of the original RNA between the primers and having additionally, at one end, a promoter sequence. This promoter sequence can be used by the appropriate RNA polymerase to make many RNA copies of the DNA. These copies can then re-enter the cycle leading to very swift amplification. With proper choice of enzymes, this amplification can be done isothermally without addition of enzymes at each cycle. Because of the cyclical nature of this process, the starting sequence can be chosen to be in the form of either DNA or RNA.

PCT Intl. Pat. Appl. Publ. No. WO 89/06700, disclose a nucleic acid sequence amplification scheme based on the hybridization of a promoter/primer sequence to a target single-stranded DNA ("ssDNA") followed by transcription of many RNA copies of the sequence. This scheme is not cyclic; *i.e.* new templates are not produced from the resultant RNA transcripts. Other amplification methods include "RACE" (Frohman, 1990), and "one-sided PCR" (Ohara, 1989) which are well-known to those of skill in the art.

Compositions and Kits for the Detection of Cancer

The present invention further provides kits for use within any of the above diagnostic methods. Such kits typically comprise two or more components necessary for performing a diagnostic assay. Components may be compounds, reagents, containers and/or equipment. For example, one container within a kit may contain a monoclonal antibody or fragment thereof that specifically binds to a lung tumor protein. Such antibodies or fragments may be provided attached to a support material, as described above. One or more additional containers may enclose elements, such as reagents or buffers, to be used in the assay. Such kits may also, or alternatively, contain a detection reagent as described above that contains a reporter group suitable for direct or indirect detection of antibody binding.

The present invention also provides kits that are suitable for performing the detection methods of the present invention. Exemplary kits comprise oligonucleotide

primer pairs each one of which specifically hybridizes to a distinct polynucleotide. Within certain embodiments, kits according to the present invention may also comprise a nucleic acid polymerase and suitable buffer. Exemplary oligonucleotide primers suitable for kits of the present invention are disclosed herein. Exemplary polynucleotides suitable for kits of the present invention are disclosed herein.

Alternatively, a kit may be designed to detect the level of mRNA encoding a lung tumor protein in a biological sample. Such kits generally comprise at least one oligonucleotide probe or primer, as described above, that hybridizes to a polynucleotide encoding a lung tumor protein. Such an oligonucleotide may be used, for example, within a PCR or hybridization assay. Additional components that may be present within such kits include a second oligonucleotide and/or a diagnostic reagent or container to facilitate the detection of a polynucleotide encoding a lung tumor protein.

In other related aspects, the present invention further provides compositions useful in the methods disclosed herein. Exemplary compositions comprise two or more oligonucleotide primer pairs each one of which specifically hybridizes to a distinct polynucleotide. Exemplary oligonucleotide primers suitable for compositions of the present invention are disclosed herein. Exemplary polynucleotides suitable for compositions of the present invention are disclosed herein.

The following Example is offered by way of illustration and not by way of limitation.

EXAMPLES

EXAMPLE 1

MULTIPLEX DETECTION OF LUNG TUMORS

A Multiplex Real-time PCR assay was established in order to simultaneously detect the expression of four lung cancer-specific genes: L762 (SEQ ID NO:1), L984 (SEQ ID NO:3), L550 (SEQ ID NO:5) and L552 (SEQ ID NO:7). In contrast to detection approaches relying on expression analysis of single lung cancer-specific genes, this Multiplex assay was able to detect all lung tumor samples tested and analyze their combined mRNA expression profile in adenocarcinoma, squamous, small cell and large cell lung tumors. L552S and L550S complement each other in detecting predominantly adenocarcinomas, L762S detects squamous cell carcinomas and L984P detects small cell carcinomas (see Table 1).

The primers and probes were designed to be intron spanning (exon specific) to eliminate any reactivity with genomic DNA making them suitable for use in blood samples without having to DNAse treat mRNA samples. They were also designed to produce amlicons of different sizes to allow gel differentiation of end products if necessary.

The assay was carried out as follows: L552S (SEQ ID NO: 7), L550 (SEQ ID NO: 5), L762 (SEQ ID NO: 1), L984 (SEQ ID NO: 3) and specific primers, and specific Taqman probes, were used to analyze their combined mRNA expression profile in lung tumors. The primers and probes are shown below:

L552S: Forward Primer (SEQ ID NO:9): 5' GACGGCATGAGCGACACACA. Reverse Primer (SEQ ID NO:10): 5' CCATGTCGCGCACTGGGATC. Probe (SEQ ID NO:11) (FAM-5' – 3'-TAMRA): CTGAAAGTCGGGATCCTACACCTGGGCA.

L550P: Forward Primer (SEQ ID NO:12): 5' GGCCACCGTCTGGATTCTTC. Reverse Primer (SEQ ID NO:13): 5' GAAGAATCCAGACGGTGGCC. Probe (SEQ ID NO:14) (FAM-5' – 3'-TAMRA): CCGCCCCAAG ATCAAATCCA CAAACC.

L762S: Forward Primer (SEQ ID NO:15): 5' ATGGCAGAGGCTGACAGACTC. Reverse Primer (SEQ ID NO:16): 5' TTCAACCACCTCAAATCCTTTCTTA. Probe (SEQ ID NO:17) (FAM-5' – 3'-TAMRA) TCGACAGCAAAGGAGAGATCAGAGCCC.

L984P: Forward Primer (SEQ ID NO:18): 5' TTACGACCCGCTCAGCCC. Reverse Primer (SEQ ID NO:19): 5' CTCCCAACGCCACTGACAA. Probe (SEQ ID NO:20) (FAM-5' – 3'-TAMRA): CCAGGCCGAGCCCCTCAGAACC.

The assay conditions were:

Taqman protocol (7700 Perkin Elmer):

In 25 µl final volume: 1x Buffer A, 5mM MgCl, 0.2 mM dCTP, 0.2 mM dATP, 0.4 mM dUTP, 0.2 mM dGTP, 0.01 U/µl AmpErase UNG, 0.0375 U/µl TaqGold, 8% (v/v) Glycerol, 0.05% (v/v) (Sigma), Gelatin, 0.05% (v/v) (Sigma), Tween20 0.1% v/v (Sigma), 300mM of each forward and reverse primer for L762P, 50mM of each forward and reverse primer from (L552S, L984P, L550S, L984P) 2 pmol of each gene specific Taqman probe (L552S, L550S, L984P) and template cDNA. The PCR reaction was carried out at one cycle at 95°C for 10 minutes, followed by 50 cycles at 95°C for 15 seconds, 60°C for 1 minute, and 68°C for 1 minute (ABI Prism 7900HO Sequence Detection System, Foster City, CA).

Since each primer set in the multiplex assay results in a band of unique length, expression signals of the four genes of interest was measured individually by agarose gel analysis. The combined expression signal of all four genes can also be measured in real-time on an ABI 7700 Prism sequence detection system (Applied Biosystems, Foster City, CA). Although specific primers have been described herein, different primer sequences, different primer or probe labeling and different detection systems could be used to perform this multiplex assay. For example, a second fluorogenic reporter dye could be incorporated for parallel detection of a reference gene by real-time PCR. Or, for example a SYBR Green detection system could be used instead of the Taqman probe approach. Table 2 shows the reactivity of the multiplex PCR with different lung tumor types and normal lung tissue.

TABLE 2 Expression of Lung Cancer Multiplex Genes (L762P, L552S, L550S, L984P) in Lung Tumor and Normal Lung

Lung Tumor Type	Positive Samples/Samples Tested
Adenocarcinoma	21/24
Squamous	17/18
Large Cell	5*/5
Small Cell	5/6
Normal Lung Tissue	0/12
Total Tumors	48/53
% Positive Tumors	90.57%

Cut-off Value = Mean normal lung +3 SD =0.901
* One sample at cut-off

EXAMPLE 2

MULTIPLEX DETECTION OF LUNG TUMORS

Six additional Multiplex Real-time PCR assays were established in order to simultaneously detect the expression of various combinations of recognized lung antigens: L762 (SEQ ID NO:1), L984 (SEQ ID NO:3), L550 (SEQ ID NO:5), L552 (SEQ ID NO:7), L763 (SEQ ID NO: 21) and L587 (SEQ ID NO:26). The six groups consisted of:

Group 1: L762, L552, L550 and L984

Group 2: L763, L552, L550 and L984

Group 3: L763, L552, L587 and L984

Group 4: L763, L550, L587 and L984

Group 5: L763, L550 and L587

Group 6: L762, L984, L550 and L587

The assays were carried out described above in Example 1 to analyze the combined mRNA expression profile in lung tumors. The primers and probes for L552S, L550P,

L762S, L984P are as described in Example 1. primers and probes for L763 and L587 are described below:

L763S: Forward Primer (SEQ ID NO:23): 5' ATTCCAGGCGACATCCTCACT. Reverse Primer (SEQ ID NO:24): 5' GTTTATCCCTGAGTCCTGTTTCCA. Probe (SEQ ID NO:25) (FAM-5' – 3'-TAMRA): TGTGCACCATTGGCTTCTAGGCACTCC.

L587: Forward Primer (SEQ ID NO:28): 5' CCCAGAGCTGTGTTAAGGGATC. Reverse Primer (SEQ ID NO:29): 5' GTTAAGCGGGATTTCATGTACGA. Probe (SEQ ID NO:30) (FAM-5' – 3'-TAMRA): AGAACCTGAACCCGTAAAGAAGCCTCCC.

The lung antigens that make up the six multiplex assays are able to detect all lung tumor samples tested and were analyzed for their combined mRNA expression profile in adenocarcinoma, squamous, small cell and large cell lung tumors. The results of these assays is presented in Table 3.

TABLE 3 Expression of Lung Cancer Multiplex Genes in Lung Tumor and Normal Lung

Lung Tumor Type	**Positive Samples/Samples Tested**					
	Group 1	**Group 2**	**Group 3**	**Group 4**	**Group 5**	**Group 6**
Adenocarcinoma	21/24	21/24	20/24	22/24	22/24	22/24
Squamous	17/18	17/18	18/18	18/18	18/18	18/18
Large Cell	5/5	3/5	4/5	3/5	3/5	4/5
Small Cell	1/2	1/2	1/2	2/2	1/2	2/2
Other	2/2	2/2	2/2	2/2	2/2	2/2
Normal Lung Tissue	0/12	0/12	0/12	0/13	0/13	0/13

Total Tumors	46/51	44/51	45/51	47/51	46/51	48/51
% Positive Tumors	90.20% CO= 0.9	86.27% CO=4.7	88.24% CO=1.08	92.16% CO=1.88	90.20% CO=2.2	94.12% CO=5.5

Cut-off Value (CO) = Mean normal lung +3 SD

Mulitplex assays using groups 1, 4 and 6 were next used to detect circulating tumor cells in peripheral blood samples from 17 lung cancer patients undergoing various types of treatments. In addition, a single gene assay using lung antigen L523 (SEQ ID NO:31) was carried out in parallel using the primers as described in SEQ ID NOs:33 and 34. Six normal donors were included as controls. The assays were carried out as described above in Example 1. The cut off value for detection in the assay being the mean of the normal lung samples + 3 standard deviations.

Group 1 antigens were detected in 5/17 samples tested. Group 4 antigens were detected in 4/17 samples and Group 6 antigens were detected in 8/17 samples. L523 was detected as a single gene in 7/17 samples tested. The combination of antigens in Group 6 was the most sensitive for lung tumor detection in tissue and blood of the groups tested.

From the foregoing it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.

CLAIMS

We Claim:

1. A method for detecting the presence of a cancer cell in a patient, said method comprising the steps of:

(a) obtaining a biological sample from said patient;

(b) contacting the biological sample with two or more oligonucleotide pairs specific for independent polynucleotide sequences which are unrelated to one another, wherein the oligonucleotide pairs hybridize, under moderately stringent conditions, to their respective polynucleotides and the complements thereof;

(c) amplifying said polynucleotides; and

(d) detecting said amplified polynucleotides;

wherein the presence of one or more of said amplified polynucleotides indicates the presence of lung cancer cells in said patient.

2. A method for determining the presence of lung cancer cells in a patient, said method comprising the steps of:

(a) obtaining a biological sample from said patient;

(b) contacting a biological sample obtained from the patient with two or more oligonucleotides that hybridize to two or more polynucleotides that encode two or more lung tumor proteins;

(c) detecting in said biological sample an amount of a polynucleotide that hybridizes to at least one of said oligonucleotides; and

(d) comparing the amount of the polynucleotides that hybridizes to said oligonucleotides to a predetermined cut-off value, and therefrom determining the presence or absence of lung cancer cells in the patient.

3. A method for monitoring the progression of lung cancer in a patient, said method comprising the steps of:

(a) obtaining a first biological sample from said patient;

(b) contacting said first biological sample with one or more oligonucleotides that hybridize to one or more polynucleotides that encode lung tumor proteins;

(c) detecting in said first biological sample an amount of at least one of said polynucleotides that hybridize to said oligonucleotides;

(d) repeating steps (b) and (c) using a second biological sample obtained from said patient at a subsequent point in time; and

(e) comparing the amount of polynucleotides detected in step (d) with the amount detected in step (c) and therefrom monitoring the progression of lung cancer in said patient.

METHODS, COMPOSITIONS AND KITS FOR THE DETECTION AND MONITORING OF LUNG CANCER

ABSTRACT OF THE DISCLOSURE

Compositions and methods for the diagnosis of lung cancer are disclosed. Such methods are useful to detect early tumors or provide adequate stage/grade information or tumor specificity. Compositions may comprise one or more lung tumor proteins, immunogenic portions thereof, or polynucleotides that encode such portions. Such compositions may be used, for example, to improve lung cancer diagnosis and prognosis and potentially differentiate between NSCLC and SCLC.

SEQUENCE LISTING

<110> Zehentner-Wilkinson, Barbara K.
Hayes, Dawn
Houghton, Raymond L.

<120> METHODS, COMPOSITIONS AND KITS FOR THE DETECTION AND MONITORING OF LUNG CANCER

<130> 609P2

<140> US
<141> 2003-09-15

<160> 34

<170> Corixa Invention Disclosure Database

<210> 1
<211> 3951
<212> DNA
<213> Homo sapiens

<400> 1
tctgcatcca tattgaaaac ctgacacaat gtatgcagca ggctcagtgt gagtgaactg 60
gaggcttctc tacaacatga cccaaaggag cattgcaggt cctatttgca acctgaagtt 120
tgtgactctc ctggttgcct taagttcaga actcccattc ctgggagctg gagtacagct 180
tcaagacaat gggtataatg gattgctcat tgcaattaat cctcaggtac ctgagaatca 240
gaacctcatc tcaaacatta aggaaatgat aactgaagct tcattttacc tatttaatgc 300
taccaagaga agagtatttt tcagaaatat aaagatttta atacctgcca catggaaagc 360
taataataac agcaaaataa aacaagaatc atatgaaaag gcaaatgtca tagtgactga 420
ctggtatggg gcacatggag atgatccata caccctacaa tacagagggt gtggaaaaga 480
gggaaaatac attcatttca cacctaattt cctactgaat gataacttaa cagctggcta 540
cggatcacga ggccgagtgt ttgtccatga atgggcccac ctccgttggg gtgtgttcga 600
tgagtataac aatgacaaac ctttctacat aaatgggcaa aatcaaatta aagtgacaag 660
gtgttcatct gacatcacag gcatttttgt gtgtgaaaaa ggtccttgcc cccaagaaaa 720
ctgtattatt agtaagcttt ttaaagaagg atgcaccttt atctacaata gcacccaaaa 780
tgcaactgca tcaataatgt tcatgcaaag tttatcttct gtggttgaat tttgtaatgc 840
aagtacccac aaccaagaag caccaaacct acagaaccag atgtgcagcc tcagaagtgc 900
atgggatgta atcacagact ctgctgactt tcaccacagc tttcccatga acgggactga 960
gcttccacct cctcccacat tctcgcttgt agaggctggt gacaaagtgg tctgtttagt 1020
gctggatgtg tccagcaaga tggcagaggc tgacagactc cttcaactac aacaagccgc 1080
agaattttat ttgatgcaga ttgttgaaat tcataccttc gtgggcattg ccagtttcga 1140
cagcaaagga gagatcagag cccagctaca ccaaattaac agcaatgatg atcgaaagtt 1200
gctggtttca tatctgccca ccactgtatc agctaaaaca gacatcagca tttgttcagg 1260
gcttaagaaa ggatttgagg tggttgaaaa actgaatgga aaagcttatg gctctgtgat 1320
gatattagtg accagcggag atgataagct tcttggcaat tgcttaccca ctgtgctcag 1380
cagtggttca acaattcact ccattgccct gggttcatct gcagccccaa atctggagga 1440
attatcacgt cttacaggag gtttaaagtt ctttgttcca gatatatcaa actccaatag 1500
catgattgat gctttcagta gaatttcctc tggaactgga gacattttcc agcaacatat 1560
tcagcttgaa agtacaggtg aaaatgtcaa acctcaccat caattgaaaa acacagtgac 1620
tgtggataat actgtgggca acgacactat gtttctagtt acgtggcagg ccagtggtcc 1680
tcctgagatt atattatttg atcctgatgg acgaaaatac tacacaaata attttatcac 1740
caatctaact tttcggacag ctagtctttg gattccagga acagctaagc ctgggcactg 1800

gacttacacc ctgaacaata cccatcattc tctgcaagcc ctgaaagtga cagtgacctc 1860
tcgcgcctcc aactcagctg tgcccccagc cactgtggaa gcctttgtgg aaagagacag 1920
cctccatttt cctcatcctg tgatgattta tgccaatgtg aaacagggat tttatcccat 1980
tcttaatgcc actgtcactg ccacagttga gccagagact ggagatcctg ttacgctgag 2040
actccttgat gatggagcag gtgctgatgt tataaaaaat gatggaattt actcgaggta 2100
ttttttctcc tttgctgcaa atggtagata tagcttgaaa gtgcatgtca atcactctcc 2160
cagcataagc accccagccc actctattcc agggagtcat gctatgtatg taccaggtta 2220
cacagcaaac ggtaatattc agatgaatgc tccaaggaaa tcagtaggca gaaatgagga 2280
ggagcgaaag tggggcttta gccgagtcag ctcaggaggc tcctttcag tgctgggagt 2340
tccagctggc ccccaccctg atgtgtttcc accatgcaaa attattgacc tggaagctgt 2400
aaaagtagaa gaggaattga ccctatcttg gacagcacct ggagaagact ttgatcaggg 2460
ccaggctaca agctatgaaa taagaatgag taaaagtcta cagaatatcc aagatgactt 2520
taacaatgct attttagtaa atacatcaaa gcgaaatcct cagcaagctg gcatcaggga 2580
gatatttacg ttctcacccc aaatttccac gaatggacct gaacatcagc caaatggaga 2640
aacacatgaa agccacagaa tttatgttgc aatacgagca atggatagga actccttaca 2700
gtctgctgta tctaacattg cccaggcgcc tctgtttatt ccccccaatt ctgatcctgt 2760
acctgccaga gattatctta tattgaaagg agttttaaca gcaatgggtt tgataggaat 2820
catttgcctt attatagttg tgacacatca tactttaagc aggaaaaaga gagcagacaa 2880
gaaagagaat ggaacaaaat tattataaat aaatatccaa agtgtcttcc ttcttagata 2940
taagacccat ggccttcgac tacaaaaaca tactaacaaa gtcaaattaa catcaaaact 3000
gtattaaaat gcattgagtt tttgtacaat acagataaga tttttacatg gtagatcaac 3060
aaattctttt tgggggtaga ttagaaaacc cttacacttt ggctatgaac aaataataaa 3120
aattattctt taaagtaatg tctttaaagg caaagggaag ggtaaagtcg gaccagtgtc 3180
aaggaaagtt tgttttattg aggtggaaaa atagccccaa gcagagaaaa ggagggtagg 3240
tctgcattat aactgtctgt gtgaagcaat catttagtta ctttgattaa tttttctttt 3300
ctccttatct gtgcagaaca ggttgcttgt ttacaactga agatcatgct atatttcata 3360
tatgaagccc ctaatgcaaa gctctttacc tcttgctatt ttgttatata tattacagat 3420
gaaatctcac tgctaatgct cagagatctt ttttcactgt aagaggtaac ctttaacaat 3480
atgggtatta ccttttgtctc ttcataccgg ttttatgaca aaggtctatt gaatttattt 3540
gtttgtaagt ttctactccc atcaaagcag ctttttaagt tattgccttg gttattatgg 3600
atgatagtta tagcccttat aatgccttaa ctaaggaaga aaagatgtta ttctgagttt 3660
gttttaatac atatatgaac atatagtttt attcaattaa accaaagaag aggtcagcag 3720
ggagatacta acctttggaa atgattagct ggctctgttt tttggttaaa taagagtctt 3780
taatcctttc tccatcaaga gttacttacc aagggcaggg gaaggggat atagaggtcc 3840
caaggaaata aaaatcatct ttcatcttta attttactcc ttcctcttat ttttttaaaa 3900
gattatcgaa caataaaatc atttgccttt ttaattaaaa acataaaaaa a 3951

<210> 2
<211> 943
<212> PRT
<213> Homo sapiens

<400> 2
Met Thr Gln Arg Ser Ile Ala Gly Pro Ile Cys Asn Leu Lys Phe Val
 1   5   10   15
Thr Leu Leu Val Ala Leu Ser Ser Glu Leu Pro Phe Leu Gly Ala Gly
            20   25   30
Val Gln Leu Gln Asp Asn Gly Tyr Asn Gly Leu Leu Ile Ala Ile Asn
        35   40   45
Pro Gln Val Pro Glu Asn Gln Asn Leu Ile Ser Asn Ile Lys Glu Met
    50   55   60
Ile Thr Glu Ala Ser Phe Tyr Leu Phe Asn Ala Thr Lys Arg Arg Val
65   70   75   80
Phe Phe Arg Asn Ile Lys Ile Leu Ile Pro Ala Thr Trp Lys Ala Asn

```
                85                  90                  95
Asn Asn Ser Lys Ile Lys Gln Glu Ser Tyr Glu Lys Ala Asn Val Ile
            100                 105                 110
Val Thr Asp Trp Tyr Gly Ala His Gly Asp Asp Pro Tyr Thr Leu Gln
        115                 120                 125
Tyr Arg Gly Cys Gly Lys Glu Gly Lys Tyr Ile His Phe Thr Pro Asn
    130                 135                 140
Phe Leu Leu Asn Asp Asn Leu Thr Ala Gly Tyr Gly Ser Arg Gly Arg
145                 150                 155                 160
Val Phe Val His Glu Trp Ala His Leu Arg Trp Gly Val Phe Asp Glu
                165                 170                 175
Tyr Asn Asn Asp Lys Pro Phe Tyr Ile Asn Gly Gln Asn Gln Ile Lys
            180                 185                 190
Val Thr Arg Cys Ser Ser Asp Ile Thr Gly Ile Phe Val Cys Glu Lys
        195                 200                 205
Gly Pro Cys Pro Gln Glu Asn Cys Ile Ile Ser Lys Leu Phe Lys Glu
    210                 215                 220
Gly Cys Thr Phe Ile Tyr Asn Ser Thr Gln Asn Ala Thr Ala Ser Ile
225                 230                 235                 240
Met Phe Met Gln Ser Leu Ser Ser Val Val Glu Phe Cys Asn Ala Ser
                245                 250                 255
Thr His Asn Gln Glu Ala Pro Asn Leu Gln Asn Gln Met Cys Ser Leu
            260                 265                 270
Arg Ser Ala Trp Asp Val Ile Thr Asp Ser Ala Asp Phe His His Ser
        275                 280                 285
Phe Pro Met Asn Gly Thr Glu Leu Pro Pro Pro Pro Thr Phe Ser Leu
    290                 295                 300
Val Glu Ala Gly Asp Lys Val Val Cys Leu Val Leu Asp Val Ser Ser
305                 310                 315                 320
Lys Met Ala Glu Ala Asp Arg Leu Leu Gln Leu Gln Gln Ala Ala Glu
                325                 330                 335
Phe Tyr Leu Met Gln Ile Val Glu Ile His Thr Phe Val Gly Ile Ala
            340                 345                 350
Ser Phe Asp Ser Lys Gly Glu Ile Arg Ala Gln Leu His Gln Ile Asn
        355                 360                 365
Ser Asn Asp Asp Arg Lys Leu Leu Val Ser Tyr Leu Pro Thr Thr Val
    370                 375                 380
Ser Ala Lys Thr Asp Ile Ser Ile Cys Ser Gly Leu Lys Lys Gly Phe
385                 390                 395                 400
Glu Val Val Glu Lys Leu Asn Gly Lys Ala Tyr Gly Ser Val Met Ile
                405                 410                 415
Leu Val Thr Ser Gly Asp Asp Lys Leu Leu Gly Asn Cys Leu Pro Thr
            420                 425                 430
Val Leu Ser Ser Gly Ser Thr Ile His Ser Ile Ala Leu Gly Ser Ser
        435                 440                 445
Ala Ala Pro Asn Leu Glu Glu Leu Ser Arg Leu Thr Gly Gly Leu Lys
    450                 455                 460
Phe Phe Val Pro Asp Ile Ser Asn Ser Asn Ser Met Ile Asp Ala Phe
465                 470                 475                 480
Ser Arg Ile Ser Ser Gly Thr Gly Asp Ile Phe Gln Gln His Ile Gln
                485                 490                 495
Leu Glu Ser Thr Gly Glu Asn Val Lys Pro His His Gln Leu Lys Asn
            500                 505                 510
Thr Val Thr Val Asp Asn Thr Val Gly Asn Asp Thr Met Phe Leu Val
```

```
        515                 520                 525
Thr Trp Gln Ala Ser Gly Pro Pro Glu Ile Ile Leu Phe Asp Pro Asp
    530                 535                 540
Gly Arg Lys Tyr Tyr Thr Asn Asn Phe Ile Thr Asn Leu Thr Phe Arg
545                 550                 555                 560
Thr Ala Ser Leu Trp Ile Pro Gly Thr Ala Lys Pro Gly His Trp Thr
                565                 570                 575
Tyr Thr Leu Asn Asn Thr His His Ser Leu Gln Ala Leu Lys Val Thr
            580                 585                 590
Val Thr Ser Arg Ala Ser Asn Ser Ala Val Pro Pro Ala Thr Val Glu
        595                 600                 605
Ala Phe Val Glu Arg Asp Ser Leu His Phe Pro His Pro Val Met Ile
    610                 615                 620
Tyr Ala Asn Val Lys Gln Gly Phe Tyr Pro Ile Leu Asn Ala Thr Val
625                 630                 635                 640
Thr Ala Thr Val Glu Pro Glu Thr Gly Asp Pro Val Thr Leu Arg Leu
                645                 650                 655
Leu Asp Asp Gly Ala Gly Ala Asp Val Ile Lys Asn Asp Gly Ile Tyr
            660                 665                 670
Ser Arg Tyr Phe Phe Ser Phe Ala Ala Asn Gly Arg Tyr Ser Leu Lys
        675                 680                 685
Val His Val Asn His Ser Pro Ser Ile Ser Thr Pro Ala His Ser Ile
    690                 695                 700
Pro Gly Ser His Ala Met Tyr Val Pro Gly Tyr Thr Ala Asn Gly Asn
705                 710                 715                 720
Ile Gln Met Asn Ala Pro Arg Lys Ser Val Gly Arg Asn Glu Glu Glu
                725                 730                 735
Arg Lys Trp Gly Phe Ser Arg Val Ser Ser Gly Gly Ser Phe Ser Val
            740                 745                 750
Leu Gly Val Pro Ala Gly Pro His Pro Asp Val Phe Pro Pro Cys Lys
        755                 760                 765
Ile Ile Asp Leu Glu Ala Val Lys Val Glu Glu Glu Leu Thr Leu Ser
    770                 775                 780
Trp Thr Ala Pro Gly Glu Asp Phe Asp Gln Gly Gln Ala Thr Ser Tyr
785                 790                 795                 800
Glu Ile Arg Met Ser Lys Ser Leu Gln Asn Ile Gln Asp Asp Phe Asn
                805                 810                 815
Asn Ala Ile Leu Val Asn Thr Ser Lys Arg Asn Pro Gln Gln Ala Gly
            820                 825                 830
Ile Arg Glu Ile Phe Thr Phe Ser Pro Gln Ile Ser Thr Asn Gly Pro
        835                 840                 845
Glu His Gln Pro Asn Gly Glu Thr His Glu Ser His Arg Ile Tyr Val
    850                 855                 860
Ala Ile Arg Ala Met Asp Arg Asn Ser Leu Gln Ser Ala Val Ser Asn
865                 870                 875                 880
Ile Ala Gln Ala Pro Leu Phe Ile Pro Pro Asn Ser Asp Pro Val Pro
                885                 890                 895
Ala Arg Asp Tyr Leu Ile Leu Lys Gly Val Leu Thr Ala Met Gly Leu
            900                 905                 910
Ile Gly Ile Ile Cys Leu Ile Ile Val Val Thr His His Thr Leu Ser
        915                 920                 925
Arg Lys Lys Arg Ala Asp Lys Lys Glu Asn Gly Thr Lys Leu Leu
    930                 935                 940
```

<210> 3
<211> 785
<212> DNA
<213> Homo sapiens

<400> 3
tctgattccg cgactccttg gccgccgctg cgcatggaaa gctctgccaa gatggagagc 60
ggcggcgccg gccagcagcc ccagccgcag ccccagcagc ccttcctgcc gcccgcagcc 120
tgtttctttg ccacggccgc agccgcggcg gccgcagccg ccgcagcggc agcgcagagc 180
gcgcagcagc agcagcagca gcagcagcag caggcgccgc agctgagacc ggcggccgac 240
ggccagccct caggggggcgg tcacaagtca gcgcccaagc aagtcaagcg acagcgctcg 300
tcttcgcccg aactgatgcg ctgcaaacgc cggctcaact tcagcggctt tggctacagc 360
ctgccgcagc agcagccggc cgccgtggcg cgccgcaacg agcgcgagcg caaccgcgtc 420
aagttggtca acctgggctt tgccaccctt cgggagcacg tccccaacgg cgcggccaac 480
aagaagatga gtaaggtgga gacactgcgc tcggcggtcg agtacatccg cgcgctgcag 540
cagctgctgg acgagcatga cgcggtgagc gccgccttcc aggcaggcgt cctgtcgccc 600
accatctccc ccaactactc caacgacttg aactccatgg ccggctcgcc ggtctcatcc 660
tactcgtcgg acgagggctc ttacgacccg ctcagccccg aggagcagga gcttctcgac 720
ttcaccaact ggttctgagg ggctcggcct ggtcaggccc tggtgcgaat ggactttgga 780
agcag 785

<210> 4
<211> 236
<212> PRT
<213> Homo sapiens

<400> 4
Met Glu Ser Ser Ala Lys Met Glu Ser Gly Gly Ala Gly Gln Gln Pro
 1   5   10   15
Gln Pro Gln Pro Gln Gln Pro Phe Leu Pro Pro Ala Ala Cys Phe Phe
            20   25   30
Ala Thr Ala Ala Ala Ala Ala Ala Ala Ala Ala Ala Ala Ala Ala Gln
        35   40   45
Ser Ala Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Ala Pro
    50   55   60
Gln Leu Arg Pro Ala Ala Asp Gly Gln Pro Ser Gly Gly Gly His Lys
65   70   75   80
Ser Ala Pro Lys Gln Val Lys Arg Gln Arg Ser Ser Ser Pro Glu Leu
                85   90   95
Met Arg Cys Lys Arg Arg Leu Asn Phe Ser Gly Phe Gly Tyr Ser Leu
            100   105   110
Pro Gln Gln Gln Pro Ala Ala Val Ala Arg Arg Asn Glu Arg Glu Arg
        115   120   125
Asn Arg Val Lys Leu Val Asn Leu Gly Phe Ala Thr Leu Arg Glu His
    130   135   140
Val Pro Asn Gly Ala Ala Asn Lys Lys Met Ser Lys Val Glu Thr Leu
145   150   155   160
Arg Ser Ala Val Glu Tyr Ile Arg Ala Leu Gln Gln Leu Leu Asp Glu
                165   170   175
His Asp Ala Val Ser Ala Ala Phe Gln Ala Gly Val Leu Ser Pro Thr
            180   185   190
Ile Ser Pro Asn Tyr Ser Asn Asp Leu Asn Ser Met Ala Gly Ser Pro
        195   200   205
Val Ser Ser Tyr Ser Ser Asp Glu Gly Ser Tyr Asp Pro Leu Ser Pro

```
    210                 215                 220
Glu Glu Gln Glu Leu Leu Asp Phe Thr Asn Trp Phe
225                 230                 235
```

<210> 5
<211> 1633
<212> DNA
<213> Homo sapiens

<400> 5
cgtggaggca gctagcgcga ggctggggag cgctgagccg cgcgtcgtgc cctgcgctgc 60
ccagactagc gaacaataca gtcgggatgg ctaaaggtga ccccaagaaa ccaaagggca 120
agacgtccgc ttatgccttc tttgtgcaga catgcagaga agaacataag aagaaaaacc 180
cagaggtccc tgtcaatttt gcggaatttt ccaagaagtg ctctgagagg tggaagacgg 240
tgtccgggaa agagaaatcc aaatttgatg aaatggcaaa ggcagataaa gtgcgctatg 300
atcgggaaat gaaggattat ggaccagcta agggaggcaa gaagaagaag gatcctaatg 360
ctcccaaaag gccaccgtct ggattcttcc tgttctgttc agaattccgc cccaagatca 420
aatccacaaa ccccggcatc tctattggag acgtggcaaa aaagctgggt gagatgtgga 480
ataatttaaa tgacagtgaa aagcagcctt acatcactaa ggcggcaaag ctgaaggaga 540
agtatgagaa ggatgttgct gactataagt cgaaaggaaa gtttgatggt gcaaagggtc 600
ctgctaaagt tgcccggaaa aaggtggaag aggaagatga agaacaggag gaggaagaag 660
aggaggagga ggaggaggag gatgaataaa gaaactgttt atctgtctcc ttgtgaatac 720
ttagagtagg ggagcgccgt aattgacaca tctcttattt gagaagtgtc tgttgccctc 780
attaggttta attacaaaat ttgatcacga tcatattgta gtctctcaaa gtgctctaga 840
aattgtcagt ggtttacatg aagtggccat gggtgtctgg agcaccctga aactgtatca 900
aagttgtaca tatttccaaa cattttaaa atgaaaaggc actctcgtgt tctcctcact 960
ctgtgcactt tgctgttggt gtgacaaggc atttaaagat gtttctggca ttttcttttt 1020
atttgtaagg tggtggtaac tatggttatt ggctagaaat cctgagtttt caactgtata 1080
tatctatagt ttgtaaaaag aacaaaacaa ccgagacaaa cccttgatgc tccttgctcg 1140
gcgttgaggc tgtggggaag atgccttttg ggagaggctg tagctcaggg cgtgcactgt 1200
gaggctggac ctgttgactc tgcaggggcc atccatttag cttcaggttg tcttgtttct 1260
gtatatagtg acatagcatt ctgctgccat cttagctgtg gacaaagggg ggtcagctgg 1320
catgagaata ttttttttta agtgcggtag tttttaaact gtttgttttt aaacaaacta 1380
tagaactctt cattgtcagc aaagcaaaga gtcactgcat caatgaaagt tcaagaacct 1440
cctgtactta aacacgattc gcaacgttct gttatttttt ttgtatgttt agaatgctga 1500
aatgtttttg aagttaaata aacagtatta cattttaga actcttctct actataacag 1560
tcaatttctg actcacagca gtgaacaaac ccccactccg ttgtatttgg agactggcct 1620
ccctataaat gtg 1633

<210> 6
<211> 200
<212> PRT
<213> Homo sapiens

<400> 6
```
Met Ala Lys Gly Asp Pro Lys Lys Pro Lys Gly Lys Met Ser Ala Tyr
 1               5                  10                  15
Ala Phe Phe Val Gln Thr Cys Arg Glu Glu His Lys Lys Lys Asn Pro
            20                  25                  30
Glu Val Pro Val Asn Phe Ala Glu Phe Ser Lys Lys Cys Ser Glu Arg
        35                  40                  45
Trp Lys Thr Met Ser Gly Lys Glu Lys Ser Lys Phe Asp Glu Met Ala
    50                  55                  60
Lys Ala Asp Lys Val Arg Tyr Asp Arg Glu Met Lys Asp Tyr Gly Pro
```

65 70 75 80
Ala Lys Gly Gly Lys Lys Lys Asp Pro Asn Ala Pro Lys Arg Pro
85 90 95
Pro Ser Gly Phe Phe Leu Phe Cys Ser Glu Phe Arg Pro Lys Ile Lys
100 105 110
Ser Thr Asn Pro Gly Ile Ser Ile Gly Asp Val Ala Lys Lys Leu Gly
115 120 125
Glu Met Trp Asn Asn Leu Asn Asp Ser Glu Lys Gln Pro Tyr Ile Thr
130 135 140
Lys Ala Ala Lys Leu Lys Glu Lys Tyr Glu Lys Asp Val Ala Asp Tyr
145 150 155 160
Lys Ser Lys Gly Lys Phe Asp Gly Ala Lys Gly Pro Ala Lys Val Ala
165 170 175
Arg Lys Lys Val Glu Glu Glu Asp Glu Glu Glu Glu Glu Glu Glu Glu
180 185 190
Glu Glu Glu Glu Glu Glu Asp Glu
195 200

<210> 7
<211> 781
<212> DNA
<213> Homo sapiens

<400> 7
gcggcggagc tgtgagccgg cgactcgggt ccctgaggtc tggattcttt ctccgctact 60
gagacacggc gggtaggtcc acaggcagat ccaactggga gttgaagtgt gagtgagagt 120
gaagaggaac cagcaggctt ccggagggtt gtgtggtcag tgactcagag tgagaaggcc 180
ctcgaagtcg tcgtccctct catgcggtgc cacgcccatg gaccttcttg tctcgtcacg 240
gccataacta gggaggaagg agggccgagg agtggagggg ctcaggcgaa gctggggtgc 300
tgttgggggt atccgagtcc cagaagcacc tggaaccccg acagaagatt ctggactccc 360
cagacgggac caggagaggg acggcatgag cgacacacac aaacacagaa ccacacagcc 420
agtcccagga gcccagtaat ggagagcccc aaaaagaaga accagcagct gaaagtcggg 480
atcctacacc tgggcagcag acagaagaag atcaggatac agctgagatc ccagtgcgcg 540
acatggaagg tgatctgcaa gagctgcatc agtcaaacac cggggataaa tctggatttg 600
ggttccggcg tcaaggtgaa gataatacct aaagaggaac actgtaaaat gccagaagca 660
ggtgaagagc aaccacaagt ttaaatgaag acaagctgaa acaacgcaag ctggttttat 720
attagatatt tgacttaaac tatctcaata aagttttgca gctttcacca aaaaaaaaaa 780
a 781

<210> 8
<211> 160
<212> PRT
<213> Homo sapiens

<400> 8
Met Arg Cys His Ala His Gly Pro Ser Cys Leu Val Thr Ala Ile Thr
1 5 10 15
Arg Glu Glu Gly Gly Pro Arg Ser Gly Gly Ala Gln Ala Lys Leu Gly
20 25 30
Cys Cys Trp Gly Tyr Pro Ser Pro Arg Ser Thr Trp Asn Pro Asp Arg
35 40 45
Arg Phe Trp Thr Pro Gln Thr Gly Pro Gly Glu Gly Arg His Glu Arg
50 55 60
His Thr Gln Thr Gln Asn His Thr Ala Ser Pro Arg Ser Pro Val Met

65 70 75 80
Glu Ser Pro Lys Lys Lys Asn Gln Gln Leu Lys Val Gly Ile Leu His
85 90 95
Leu Gly Ser Arg Gln Lys Lys Ile Arg Ile Gln Leu Arg Ser Gln Cys
100 105 110
Ala Thr Trp Lys Val Ile Cys Lys Ser Cys Ile Ser Gln Thr Pro Gly
115 120 125
Ile Asn Leu Asp Leu Gly Ser Gly Val Lys Val Lys Ile Ile Pro Lys
130 135 140
Glu Glu His Cys Lys Met Pro Glu Ala Gly Glu Glu Gln Pro Gln Val
145 150 155 160

<210> 9
<211> 20
<212> DNA
<213> Homo sapiens

<400> 9
gacggcatga gcgacacaca 20

<210> 10
<211> 20
<212> DNA
<213> Homo sapiens

<400> 10
ccatgtcgcg cactgggatc 20

<210> 11
<211> 28
<212> DNA
<213> Homo sapiens

<400> 11
ctgaaagtcg ggatcctaca cctgggca 28

<210> 12
<211> 20
<212> DNA
<213> Homo sapiens

<400> 12
ggccaccgtc tggattcttc 20

<210> 13
<211> 20
<212> DNA
<213> Homo sapiens

<400> 13
gaagaatcca gacggtggcc 20

<210> 14

<211> 26
<212> DNA
<213> Homo sapiens

<400> 14
ccgccccaag atcaaatcca caaacc 26

<210> 15
<211> 21
<212> DNA
<213> Homo sapiens

<400> 15
atggcagagg ctgacagact c 21

<210> 16
<211> 25
<212> DNA
<213> Homo sapiens

<400> 16
ttcaaccacc tcaaatcctt tctta 25

<210> 17
<211> 27
<212> DNA
<213> Homo sapiens

<400> 17
tcgacagcaa aggagagatc agagccc 27

<210> 18
<211> 18
<212> DNA
<213> Homo sapiens

<400> 18
ttacgacccg ctcagccc 18

<210> 19
<211> 19
<212> DNA
<213> Homo sapiens

<400> 19
ctcccaacgc cactgacaa 19

<210> 20
<211> 22
<212> DNA
<213> Homo sapiens

<400> 20
ccaggccgag cccctcagaa cc 22

<210> 21
<211> 1800
<212> DNA
<213> Homo sapiens

<400> 21
gcgcctcatt gccactgcag tgactaaagc tgggaagacg ctggtcagtt cacctgcccc 60
actggttgtt ttttaaacaa attctgatac aggcgacatc ctcactgacc gagcaaagat 120
tgacattcgt atcatcactg tgcaccattg gcttctaggc actccagtgg ggtaggagaa 180
ggaggtctga aaccctcgca gagggatctt gccctcattc tttgggtctg aaacactggc 240
agtcgttgga aacaggactc agggataaac cagcgcaatg gattggggga cgctgcacac 300
tttcatcggg ggtgtcaaca aacactccac cagcatcggg aaggtgtgga tcacagtcat 360
ctttatttc cgagtcatga tcctagtggt ggctgcccag gaagtgtggg gtgacgagca 420
agaggacttc gtctgcaaca cactgcaacc gggatgcaaa aatgtgtgct atgaccactt 480
tttcccggtg tcccacatcc ggctgtgggc cctccagctg atcttcgtct ccacccccagc 540
gctgctggtg gccatgcatg tggcctacta caggcacgaa accactcgca agttcaggcg 600
aggagagaag aggaatgatt tcaaagacat agaggacatt aaaaagcaca aggttcggat 660
agaggggtcg ctgtggtgga cgtacaccag cagcatcttt ttccgaatca tctttgaagc 720
agcctttatg tatgtgtttt acttccttta caatgggtac cacctgccct gggtgttgaa 780
atgtgggatt gacccctgcc ccaaccttgt tgactgcttt atttctaggc caacagagaa 840
gaccgtgttt accatttta tgatttctgc gtctgtgatt tgcatgctgc ttaacgtggc 900
agagttgtgc tacctgctgc tgaaagtgtg ttttaggaga tcaaagagag cacagacgca 960
aaaaaatcac cccaatcatg ccctaaagga gagtaagcag aatgaaatga atgagctgat 1020
ttcagatagt ggtcaaaatg caatcacagg tttcccaagc taaacatttc aaggtaaaat 1080
gtagctgcgt cataaggaga cttctgtctt ctccagaagg caataccaac ctgaaagttc 1140
cttctgtagc ctgaagagtt tgtaaatgac tttcataata aatagacact tgagttaact 1200
ttttgtagga tacttgctcc attcatacac aacgtaatca aatatgtggt ccatctctga 1260
aaacaagaga ctgcttgaca aaggagcatt gcagtcactt tgacaggttc cttttaagtg 1320
gactctctga caaagtgggt actttctgaa aatttatata actgttgttg ataaggaaca 1380
tttatccagg aattgatacg tttattagga aaagatattt ttataggctt ggatgttttt 1440
agttccgact ttgaatttat ataaagtatt tttataatga ctggtcttcc ttacctggaa 1500
aaacatgcga tgttagtttt agaattacac cacaagtatc taaatttcca acttacaaag 1560
ggtcctatct tgtaaatatt gttttgcatt gtctgttggc aaatttgtga actgtcatga 1620
tacgcttaag gtgggaaagt gttcattgca caatatattt ttactgcttt ctgaatgtag 1680
acggaacagt gtggaagcag aaggcttttt taactcatcc gtttggccga tcgttgcaga 1740
ccactgggag atgtggatgt ggttgcctcc ttttgctcgt ccccgtggct taacccttct 1800

<210> 22
<211> 261
<212> PRT
<213> Homo sapiens

<400> 22
Met Asp Trp Gly Thr Leu His Thr Phe Ile Gly Gly Val Asn Lys His
 1   5   10   15
Ser Thr Ser Ile Gly Lys Val Trp Ile Thr Val Ile Phe Ile Phe Arg
            20   25   30
Val Met Ile Leu Val Val Ala Ala Gln Glu Val Trp Gly Asp Glu Gln
        35   40   45
Glu Asp Phe Val Cys Asn Thr Leu Gln Pro Gly Cys Lys Asn Val Cys
    50   55   60
Tyr Asp His Phe Phe Pro Val Ser His Ile Arg Leu Trp Ala Leu Gln
65   70   75   80

```
Leu Ile Phe Val Ser Thr Pro Ala Leu Leu Val Ala Met His Val Ala
                85                  90                  95
Tyr Tyr Arg His Glu Thr Thr Arg Lys Phe Arg Arg Gly Glu Lys Arg
            100                 105                 110
Asn Asp Phe Lys Asp Ile Glu Asp Ile Lys Lys His Lys Val Arg Ile
        115                 120                 125
Glu Gly Ser Leu Trp Trp Thr Tyr Thr Ser Ser Ile Phe Phe Arg Ile
    130                 135                 140
Ile Phe Glu Ala Ala Phe Met Tyr Val Phe Tyr Phe Leu Tyr Asn Gly
145                 150                 155                 160
Tyr His Leu Pro Trp Val Leu Lys Cys Gly Ile Asp Pro Cys Pro Asn
                165                 170                 175
Leu Val Asp Cys Phe Ile Ser Arg Pro Thr Glu Lys Thr Val Phe Thr
            180                 185                 190
Ile Phe Met Ile Ser Ala Ser Val Ile Cys Met Leu Leu Asn Val Ala
        195                 200                 205
Glu Leu Cys Tyr Leu Leu Leu Lys Val Cys Phe Arg Arg Ser Lys Arg
    210                 215                 220
Ala Gln Thr Gln Lys Asn His Pro Asn His Ala Leu Lys Glu Ser Lys
225                 230                 235                 240
Gln Asn Glu Met Asn Glu Leu Ile Ser Asp Ser Gly Gln Asn Ala Ile
                245                 250                 255
Thr Gly Phe Pro Ser
            260
```

<210> 23
<211> 21
<212> DNA
<213> Homo sapiens

<400> 23
attccaggcg acatcctcac t 21

<210> 24
<211> 24
<212> DNA
<213> Homo sapiens

<400> 24
gtttatccct gagtcctgtt tcca 24

<210> 25
<211> 27
<212> DNA
<213> Homo sapiens

<400> 25
tgtgcaccat tggcttctag gcactcc 27

<210> 26
<211> 2257
<212> DNA

<213> Homo sapiens

<400> 26
attttgctta cagagtcccg tctcaccatc ctgggcttcc aacggagact gcggtatccg 60
cggctggaga cccagcggcg agtagccttt tgctcccgga cggacttgag aggcttaaag 120
gatggcctcg tcagatctgg aacaattatg ctctcatgtt aatgaaaaga ttggcaatat 180
taagaaaacc ttatcattaa gaaactgtgg ccaggaacct accttgaaaa ctgtattaaa 240
taaaatagga gatgagatca ttgtaataaa tgaacttcta aataaattgg aattggaaat 300
tcagtatcaa gaacaaacca acaattcact caaggaactc tgtgaatctc ttgaagaaga 360
ttacaaagac atagaacatc ttaaagaaaa cgttccttcc catttgcctc aagtaacagt 420
aacccagagc tgtgttaagg gatcagatct tgatcctgaa gaaccaatca aagttgaaga 480
acctgaaccc gtaaagaagc ctcccaaaga gcaaagaagt attaaggaaa tgccatttat 540
aacttgtgat gagttcaatg gtgttccttc gtacatgaaa tcccgcttaa cctataatca 600
aattaatgat gttattaaag aaatcaacaa ggcagtaatt agtaaatata aaatcctaca 660
tcagccaaaa aagtctatga attctgtgac cagaaatctc tatcacagat ttattgatga 720
agaaacgaag gataccaaag gtcgttattt tatagtggaa gctgacataa aggagttcac 780
aactttgaaa gctgacaaga agtttcacgt gttactgaat attttacgac actgccggag 840
gctatcagag gtccgagggg gaggacttac tcgttatgtt ataacctgag tcccttgtga 900
acttttgaac ataccaacag ggtatagagt atagaggcta tttctataat tttcttatat 960
ataatttttt taacttttaa tctttttttgt ttcctttttt ttttttttga gacaggatct 1020
tgctttgtca cccaggggct tgctttgtca cgcaggctag agtgcagtgg cgcaaacatg 1080
gctcactgca gcctcaacct cccaggctca agtgatcctc ccacctcagc cccctgaatg 1140
gctgggacta caagcgtgcg ccaccatgcc tggctaattt ttgtattttt tggagagatg 1200
gggtttcacc atgttgccta ggctggtctt gagctcctga gctcaaacaa tccaccctcc 1260
tcagcctccc aaagtgctgg gattacaggc ttgagccacc acacctgacc tattcttgtt 1320
tcttataaaa ataaaacttt tttggataaa gcttatttct tgtttttttc tttttctttt 1380
ttttttttt tcgagactcc atctcagaaa aaaagaaaaa aagactgggt acagatgtga 1440
tattggaaga aaaagatcaa gctgatgagg ttaggatacc caggcccttt ggacttaaag 1500
atcactagtg tctaaattcc atcgatggca tttcagtcta taggtaaact tcctggaagc 1560
tggatttgga gacagtttat catctgatta ttgggctttc gtataggtcc ttagggagca 1620
gcttacctga aatgcattta gtgtacacca gtctgtaaac ttcaacctgt aatgaaagtg 1680
taataaatgt acattgagtt gatgtgataa tgtgatataa taagaaatat atatttgatc 1740
ttcctatcta gttccttgtt cagagctcct aaaaccttg taatttccaa agtgatggag 1800
tacatctttt gttctagtat ttggtctttg accccagttc ctgacacaaa gctcctaaat 1860
tcctttaaat ttcccagtga taggagaatt ttttgttcta atgaggtcac tcttgatggg 1920
cacctggata actcaggatg ggggctgctc acaaagacca catcatgatt ggaagtttca 1980
aactttcagt ctcccacctc cagagagggg agaggggctg gagatttgtg tcaataatcc 2040
atcaggccta tgtcaacaag acataatccg ttaactatgg agttcaggga gcttcagggt 2100
tggcaaacat tttgatgtgc caggaaggtg acgcactcca gctttatgaa gtcagcaagt 2160
cctgtgctca ggatgcttyt ggaccttgcc ccaggtaccc cttcatgtgg ctgttgttca 2220
tctgtatcct ttgtagtagc cttaaaataa actgtta 2257

<210> 27
<211> 255
<212> PRT
<213> Homo sapiens

<400> 27
Met Ala Ser Ser Asp Leu Glu Gln Leu Cys Ser His Val Asn Glu Lys
 1   5   10   15
Ile Gly Asn Ile Lys Lys Thr Leu Ser Leu Arg Asn Cys Gly Gln Glu
            20   25   30
Pro Thr Leu Lys Thr Val Leu Asn Lys Ile Gly Asp Glu Ile Ile Val

```
        35                  40                  45
Ile Asn Glu Leu Leu Asn Lys Leu Glu Leu Glu Ile Gln Tyr Gln Glu
    50                  55                  60
Gln Thr Asn Asn Ser Leu Lys Glu Leu Cys Glu Ser Leu Glu Glu Asp
65                  70                  75                  80
Tyr Lys Asp Ile Glu His Leu Lys Glu Asn Val Pro Ser His Leu Pro
                85                  90                  95
Gln Val Thr Val Thr Gln Ser Cys Val Lys Gly Ser Asp Leu Asp Pro
            100                 105                 110
Glu Glu Pro Ile Lys Val Glu Glu Pro Glu Pro Val Lys Lys Pro Pro
        115                 120                 125
Lys Glu Gln Arg Ser Ile Lys Glu Met Pro Phe Ile Thr Cys Asp Glu
    130                 135                 140
Phe Asn Gly Val Pro Ser Tyr Met Lys Ser Arg Leu Thr Tyr Asn Gln
145                 150                 155                 160
Ile Asn Asp Val Ile Lys Glu Ile Asn Lys Ala Val Ile Ser Lys Tyr
                165                 170                 175
Lys Ile Leu His Gln Pro Lys Lys Ser Met Asn Ser Val Thr Arg Asn
            180                 185                 190
Leu Tyr His Arg Phe Ile Asp Glu Glu Thr Lys Asp Thr Lys Gly Arg
        195                 200                 205
Tyr Phe Ile Val Glu Ala Asp Ile Lys Glu Phe Thr Thr Leu Lys Ala
    210                 215                 220
Asp Lys Lys Phe His Val Leu Leu Asn Ile Leu Arg His Cys Arg Arg
225                 230                 235                 240
Leu Ser Glu Val Arg Gly Gly Gly Leu Thr Arg Tyr Val Ile Thr
                245                 250                 255
```

<210> 28
<211> 22
<212> DNA
<213> Homo sapiens

<400> 28
cccagagctg tgttaaggga tc 22

<210> 29
<211> 23
<212> DNA
<213> Homo sapiens

<400> 29
gttaagcggg atttcatgta cga 23

<210> 30
<211> 28
<212> DNA
<213> Homo sapiens

<400> 30
agaacctgaa cccgtaaaga agcctccc 28

<210> 31
<211> 1740
<212> DNA
<213> Homo sapiens

<400> 31
atgaacaaac tgtatatcgg aaacctcagc gagaacgccg ccccctcgga cctagaaagt 60
atcttcaagg acgccaagat cccggtgtcg ggacccttcc tggtgaagac tggctacgcg 120
ttcgtggact gcccggacga gagctgggcc ctcaaggcca tcgaggcgct ttcaggtaaa 180
atagaactgc acgggaaacc catagaagtt gagcactcgg tcccaaaaag gcaaaggatt 240
cggaaacttc agatacgaaa tatcccgcct catttacagt gggaggtgct ggatagttta 300
ctagtccagt atggagtggt ggagagctgt gagcaagtga acactgactc ggaaactgca 360
gttgtaaatg taacctattc cagtaaggac caagctagac aagcactaga caaactgaat 420
ggatttcagt tagagaattt caccttgaaa gtagcctata tccctgatga aacggccgcc 480
cagcaaaacc ccttgcagca gccccgaggt cgccgggggc ttgggcagag gggctcctca 540
aggcaggggt ctccaggatc cgtatccaag cagaaaccat gtgatttgcc tctgcgcctg 600
ctggttccca cccaatttgt tggagccatc ataggaaaag aaggtgccac cattcggaac 660
atcaccaaac agacccagtc taaaatcgat gtccaccgta aagaaaatgc gggggctgct 720
gagaagtcga ttactatcct ctctactcct gaaggcacct ctgcggcttg taagtctatt 780
ctggagatta tgcataagga agctcaagat ataaaattca cagaagagat ccccttgaag 840
attttagctc ataataactt tgttggacgt cttattggta aagaaggaag aaatcttaaa 900
aaaattgagc aagacacaga cactaaaatc acgatatctc cattgcagga attgacgctg 960
tataatccag aacgcactat tacagttaaa ggcaatgttg agacatgtgc caaagctgag 1020
gaggagatca tgaagaaaat cagggagtct tatgaaaatg atattgcttc tatgaatctt 1080
caagcacatt taattcctgg attaaatctg aacgccttgg gtctgttccc acccacttca 1140
gggatgccac ctcccacctc agggcccccc tcagccatga ctcctcccta cccgcagttt 1200
gagcaatcag aaacggagac tgttcatctg tttatcccag ctctatcagt cggtgccatc 1260
atcggcaagc agggccagca catcaagcag ctttctcgct ttgctggagc ttcaattaag 1320
attgctccag cggaagcacc agatgctaaa gtgaggatgg tgattatcac tggaccacca 1380
gaggctcagt tcaaggctca gggaagaatt tatggaaaaa ttaaagaaga aaactttgtt 1440
agtcctaaag aagaggtgaa acttgaagct catatcagag tgccatcctt tgctgctggc 1500
agagttattg gaaaaggagg caaaacggtg aatgaacttc agaatttgtc aagtgcagaa 1560
gttgttgtcc ctcgtgacca gacacctgat gagaatgacc aagtggttgt caaaataact 1620
ggtcacttct atgcttgcca ggttgcccag agaaaaattc aggaaattct gactcaggta 1680
aagcagcacc aacaacagaa ggctctgcaa agtggaccac ctcagtcaag acggaagtaa 1740

<210> 32
<211> 579
<212> PRT
<213> Homo sapiens

<400> 32
Met Asn Lys Leu Tyr Ile Gly Asn Leu Ser Glu Asn Ala Ala Pro Ser
 1   5   10   15
Asp Leu Glu Ser Ile Phe Lys Asp Ala Lys Ile Pro Val Ser Gly Pro
            20   25   30
Phe Leu Val Lys Thr Gly Tyr Ala Phe Val Asp Cys Pro Asp Glu Ser
        35   40   45
Trp Ala Leu Lys Ala Ile Glu Ala Leu Ser Gly Lys Ile Glu Leu His
    50   55   60
Gly Lys Pro Ile Glu Val Glu His Ser Val Pro Lys Arg Gln Arg Ile

```
65                  70                  75                  80
Arg Lys Leu Gln Ile Arg Asn Ile Pro Pro His Leu Gln Trp Glu Val
                85                  90                  95
Leu Asp Ser Leu Leu Val Gln Tyr Gly Val Val Glu Ser Cys Glu Gln
            100                 105                 110
Val Asn Thr Asp Ser Glu Thr Ala Val Val Asn Val Thr Tyr Ser Ser
        115                 120                 125
Lys Asp Gln Ala Arg Gln Ala Leu Asp Lys Leu Asn Gly Phe Gln Leu
    130                 135                 140
Glu Asn Phe Thr Leu Lys Val Ala Tyr Ile Pro Asp Glu Thr Ala Ala
145                 150                 155                 160
Gln Gln Asn Pro Leu Gln Gln Pro Arg Gly Arg Arg Gly Leu Gly Gln
                165                 170                 175
Arg Gly Ser Ser Arg Gln Gly Ser Pro Gly Ser Val Ser Lys Gln Lys
            180                 185                 190
Pro Cys Asp Leu Pro Leu Arg Leu Leu Val Pro Thr Gln Phe Val Gly
        195                 200                 205
Ala Ile Ile Gly Lys Glu Gly Ala Thr Ile Arg Asn Ile Thr Lys Gln
    210                 215                 220
Thr Gln Ser Lys Ile Asp Val His Arg Lys Glu Asn Ala Gly Ala Ala
225                 230                 235                 240
Glu Lys Ser Ile Thr Ile Leu Ser Thr Pro Glu Gly Thr Ser Ala Ala
                245                 250                 255
Cys Lys Ser Ile Leu Glu Ile Met His Lys Glu Ala Gln Asp Ile Lys
            260                 265                 270
Phe Thr Glu Glu Ile Pro Leu Lys Ile Leu Ala His Asn Asn Phe Val
        275                 280                 285
Gly Arg Leu Ile Gly Lys Glu Gly Arg Asn Leu Lys Lys Ile Glu Gln
    290                 295                 300
Asp Thr Asp Thr Lys Ile Thr Ile Ser Pro Leu Gln Glu Leu Thr Leu
305                 310                 315                 320
Tyr Asn Pro Glu Arg Thr Ile Thr Val Lys Gly Asn Val Glu Thr Cys
                325                 330                 335
Ala Lys Ala Glu Glu Glu Ile Met Lys Lys Ile Arg Glu Ser Tyr Glu
            340                 345                 350
Asn Asp Ile Ala Ser Met Asn Leu Gln Ala His Leu Ile Pro Gly Leu
        355                 360                 365
Asn Leu Asn Ala Leu Gly Leu Phe Pro Pro Thr Ser Gly Met Pro Pro
    370                 375                 380
Pro Thr Ser Gly Pro Pro Ser Ala Met Thr Pro Pro Tyr Pro Gln Phe
385                 390                 395                 400
Glu Gln Ser Glu Thr Glu Thr Val His Leu Phe Ile Pro Ala Leu Ser
                405                 410                 415
Val Gly Ala Ile Ile Gly Lys Gln Gly Gln His Ile Lys Gln Leu Ser
            420                 425                 430
Arg Phe Ala Gly Ala Ser Ile Lys Ile Ala Pro Ala Glu Ala Pro Asp
        435                 440                 445
Ala Lys Val Arg Met Val Ile Ile Thr Gly Pro Pro Glu Ala Gln Phe
    450                 455                 460
Lys Ala Gln Gly Arg Ile Tyr Gly Lys Ile Lys Glu Glu Asn Phe Val
465                 470                 475                 480
Ser Pro Lys Glu Glu Val Lys Leu Glu Ala His Ile Arg Val Pro Ser
                485                 490                 495
Phe Ala Ala Gly Arg Val Ile Gly Lys Gly Gly Lys Thr Val Asn Glu
```

```
            500                 505                 510
Leu Gln Asn Leu Ser Ser Ala Glu Val Val Val Pro Arg Asp Gln Thr
        515                 520                 525
Pro Asp Glu Asn Asp Gln Val Val Val Lys Ile Thr Gly His Phe Tyr
    530                 535                 540
Ala Cys Gln Val Ala Gln Arg Lys Ile Gln Glu Ile Leu Thr Gln Val
545                 550                 555                 560
Lys Gln His Gln Gln Gln Lys Ala Leu Gln Ser Gly Pro Pro Gln Ser
                565                 570                 575
Arg Arg Lys
```

<210> 33
<211> 21
<212> DNA
<213> Homo sapiens

<400> 33
catggactgg ctttctggtt g 21

<210> 34
<211> 24
<212> DNA
<213> Homo sapiens

<400> 34
ctgagaaaag ctctggcctt aaac 24